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Complement is activated via two pathways: classical (CCP) and
alternative (ACP). The CCP has been demonstrated in the nurse
shark. The ACP has not been demonstrated in any cartilagenous
fish. Nurse shark serum was evaluated for complement activity
by its ability to lyse heterologous erythrocytes. As CCP
activity requires calcium and magnesium, activity of shark
serum chelated with EGTA (a selective calcium chelator) or
EDTA (a chelator of calcium and magnesium) was assessed.
Activity remained in serum chelated with EGTA but not EDTA.
Furthermore, activity of chelated serum was enhanced by added
magnesium. Activation of shark complement by activators of
mammalian ACP (zymosan, LPS, inulin, CVF) was assessed.
Complement was activated by zymosan and LPS. Immunoblots were
employed, with limited success, to demonstrate complement
proteins in nurse shark serum. This study unequivocally
demonstrates that the ACP is present in the primitive nurse
shark.
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INTRODUCTION
The discovery of a protein in human serum termed
properdin led Pillemer and his colleagues to propose the
discovery of a new system for natural resistance to
infection in which properdin activated the complement
component 03 when complexed with certain substances
(Pillemer et al., 1954; Pillemer et al., 1955). Pillemer's
properdin system was thought to consist of properdin,
magnesium and the four complement components known at that
time (C1, C2, C3 and C4). His experimental results
determined that the system required a heat labile factor and
a hydrazine sensitive factor which was interpreted as
indicating a requirement for Cl, C2 and 04. The properdin
system was proposed as a mechanism by which substances such
as dextrans, levans, bacterial cell walls and other
bacterial carbohydrates could directly activate complement
via properdin; therefore bypassing the need for specific
antigen/antibody complexes which were required to activate
the classical pathway of complement. Nelson (1958) later
suggested that the depletion of 03 activity by zymosan (a
substance prepared from the cell walls of yeast and used
extensively, although not exclusively, by Pillemer) could
be explained by the presence of natural antibodies to
zymosan in human serum which, in complex with zymosan, could
activate the classical pathway of complement. This study,
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along with others, (Cowan, 1958; Toussaint and Muschel,
1959) brought a skepticism to the theory of the properdin
pathway as a newly discovered mediator of natural immunity.
Pillemer's theory fell into disfavor as a result of these
publications. It was not until the early 1970's that
experimental evidence began to accumulate which strongly
supported the original concept of Pillemer (Sandberg et al.,
1970; Sandberg and Osler, 1971; Sandberg et al., 1971; Gotze
and Muller-Eberhard, 1971; Brade et al., 1971) although
properdin was not as central to the system as originally
proposed (Medicus et al., 1976). The apparent discrepancy
arising from Pillemer and Nelson's studies was resolved by
studies showing that the hemolytic activity of the
alternative pathway, as the properdin pathway is now called,
is enhanced by antibody, however antibody is not essential
for the activation of the pathway (Schenken and Ruddy, 1981;
Nelson and Ruddy, 1976; Polhill et al., 1978). In addition,
these later studies have shown that the enhancement of
alternative pathway activity by antibody is mediated by the
Fab portion of the antibody molecule rather than the Fc
portion which activates the classical pathway via its
interaction with ClG (Sandberg et al., 1971).
The classical and the alternative complement pathway
have been well characterized in mammals (Reid, 1976). The
two pathways have requirements for activation that are
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distinct from each other. With the exception of C3, which
is common to both pathways, the serum protein components
generating and controlling the C3 and C5 convertases of the
classical pathway are separate from those of the alternative
pathway. Activation of the classical pathway is initiated
mainly by interaction of the C1 subunit of C1 with the Fc
regions of IgG or IgM in complex with specific antigen.
Activation of the classical pathway can however occur in the
absence of specific antibody, for example on the surface of
certain microorganisms and by polyanionic molecules like
DNA, carrageenan and heparin. The significance of this type
of activation in a physiological system is unknown (Abbas et
al., 1991). Once bound to the activating substance, a
change in the conformation of the C1q molecule occurs which
then allows activation of Clr which in turn activates Cls.
The integrity of the Clr2Clsz tetramer is dependent on
calcium ions, as in the absence of these ions the tetramer
dissociates into a C1r2 dimer and 2 Cls chains (Reid, 1986).
Activated Cls, a serine protease, within the C1 complex
cleaves 04 into C4a and C4b. This is an amplification step
as activated Cl can cleave many C4 molecules. The C4b
molecule, via its reactive thiolester, then becomes bound to
the surface of the activator and the proenzyme C2 associates
with C4b in a magnesium-dependent reaction to be cleaved by
Cls to form C4bC2b, the 03 convertase of the classical
pathway. C2b is a serine protease and is responsible for
3
the subsequent cleavage of C3 by the classical pathway C3
convertase.
The alternative pathway is activated directly on the
surface of activating particles such as lipopolysaccharides,
pure polysaccharides, bacteria, fungi, tumor cells, red
blood cells, parasites and aggregates of immunoglobulins in
particulate form without requiring specific antibody (Gotze
and Muller-Eberhard, 1976). A low level of C3b must be
available in serum in order to initiate the formation of the
alternative pathway C3 convertase i.e. C3bBb. This is
provided by the continuous generation of a C3b-like
molecule, C3(H20), by slow hydrolysis of the internal
thiolester bond in the alpha chain of C3. This molecule can
then complex with factor B in a magnesium-dependent reaction
to form C3(H 20)B. Factor B in this complex now becomes
susceptible to cleavage by the enzyme, factor D, to form a
C3 convertase, C3(H 20)Bb which is capable of generating a
low level of C3b (Pangburn and Muller-Eberhard, 1980).
Factor B subsequently binds to true C3b in a magnesium-
dependent reaction where it is again susceptible to cleavage
by factor D. If this occurs on the surface of a suitable
activator of the pathway a stable 03 convertase, C3bBb, is
formed. The alternative pathway activator is thought to
provide a site at which C3b and C3bBb are protected from
rapid decay by the endogenous control proteins factor I (C3b
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inactivator) and factor H (beta 1 H) (Fearon and Austen,
1977). Bb is a serine protease and is responsible for the
C3 cleaving activity of the alternative pathway 03
convertase. The hydrazine-sensitive factor and the heat-
labile factor originally described by Pillemer are now known
to be C3 and factor B respectively (Medicus et al., 1976).
Once the C3 convertase is formed, the reaction becomes
amplified whereby large amounts of C3b become deposited on
the surface of the activator. Properdin is now known to act
late in the activation pathway as a stabilizer for the
already formed 03 and C5 convertases (Nedicus et al., 1976).
The binding of a molecule of C3b to either C4bC2b or C3bBb
changes the specificity of the convertases from C3-cleaving
activity to C5-cleaving activity generating identical
fragments, C5a and C5b. Once 05 has been cleaved by either
of the two convertases, both pathways share the common
terminal components C6, C7, C8 and 09 which form the
membrane attack complex (MAC).
Thus, activation of the classical pathway is dependent
on the presence of calcium and magnesium ions whereas
activation of the alternative pathway requires only
magnesium ions. This difference in divalent cation
requirement can be used to selectively inhibit classical
pathway activity by removal of calcium ions while
demonstrating complement activity exclusively by the
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alternative pathway. The C1 complex of the classical
pathway is easily dissociated in the presence of calcium
chelators such as ethylene diaminetetra acetic acid (EDTA)
and ethyleneglycol-bis-(beta-amino ethyl ether) N,N,N,N-
tetra acetic acid (EGTA) (Reid, 1986). EDTA is a strong
chelator of calcium, magnesium and other metal ions, and
therefore will prevent activation of both complement
pathways. EGTA is a selective chelator of calcium ions as
the avidity of EGTA for calcium is about 100,000 times
greater than its avidity for magnesium (Bryant and Jenkins,
1968) and therefore will prevent activation of the classical
but not the alternative pathway.
The complement system is responsible for the generation
of anaphylatoxins, C3a and C5a, which are powerful
chemotaxic and inflammatory effectors. The potent opsonin,
C3b, is also generated by the activation of complement.
Lysis of foreign erythrocytes is perhaps not the most
important physiological function of complement, however, in
vitro, hemolytic assays have been used routinely to measure
complement activity because cell damage is easily detected
and quantitated by measurement of hemoglobin released into
the medium (Muller-Eberhard, 1969). Chelation of calcium
and subsequent demonstration of lytic activity (i.e. in the
presence of EGTA) is an indication of the functioning of the
alternative pathway since only magnesium is required for
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this pathway to proceed. EDTA will abolish hemolytic
activity by either pathway as it is a strong chelator of
both calcium and magnesium ions.
In hemolytic assays employing sensitized sheep or
unsensitized rabbit erythrocytes as targets, both human and
guinea pig serum showed ability to lyse these target cells,
although activity against sensitized sheep was greater than
against rabbit cells (Platts-Nills and Ishizaka, 1974). The
lysis of sheep erythrocytes, sensitized with either 7s or
19s hemolysin, by human or guinea pig serum is completely
blocked in the presence of 8 mM EGTA. Conversely, the same
serum shows greater than 90% hemolysis of unsensitized
rabbit cells in the presence of 8 mn EGTA and 2 mM Mg++
(Platts-Mills and Ishizaka, 1974). These results
demonstrate that in mammalian serum the lysis of sensitized
sheep erythrocytes is mediated primarily by the classical
pathway whereas the lysis of rabbit erythrocytes is mediated
by the alternative pathway.
The abrogation of hemolytic activity of serum by
incubation with alternative pathway activators such as
zymosan, Cobra venom factor (CVF), lipopolysaccharide (LPS)
and inulin reflects activation of complement with
consumption of the terminal complement components. As these
components are common to both pathways, activation of either
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pathway results in consumption of the terminal components
such that they are no longer available to effect the lysis
of target cells regardless of the presence of early acting
components of the other pathway. The ability of alternative
pathway activators to abolish the hemolytic activity of
serum in the absence of specific antibody is considered to
be a criterion for demonstration of alternative pathway
activity in a serum sample. These functional
characteristics have been used to evaluate complement
activity in mammals as well as lower vertebrate species.
Ohta et al. (1984) reported the lysis of sheep
erythrocytes, sensitized with rabbit antibody (hemolysin),
by chicken complement was blocked by 4 M EDTA or 4 mM EGTA
and this activity was not restored by the addition of
magnesium ions. From these observations they concluded that
calcium ions were required for the lysis of sensitized sheep
erythrocytes by chicken complement. However, lysis of
unsensitized horse erythrocytes was blocked only at a
concentration of 12 mM EGTA and was completely restored by
the addition of 4-6 mM magnesium indicating that a calcium
independent lytic pathway was responsible for the lysis of
horse erythrocytes by chicken complement. Absorption of
serum with horse erythrocytes and employing serum of
bursectomized chickens (Bursa of Fabricius is the site of
antibody production in birds) showed that the lysis of horse
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erythrocytes by chicken serum was antibody-independent.
Depletion of serum hemolytic activity by alternative pathway
activators and selective inhibition of activity by chelators
was reported (Ellis et al., 1989) for turkey serum. Results
obtained were similar to those seen with chicken serum.
Thus, activity of the classical and the alternative pathway
can be demonstrated in birds using the same functional
criteria used to distinguish the activity of the two
complement pathways in mammals. Additionally, horse
erythrocytes appear to be efficiently lysed via the
alternative pathway in these birds.
Complement activity has been demonstrated in
ectothermic vertebrates using functional assays similar to
those described for mammals and birds. To date, the
presence of alternative pathway activity has been
established in representatives of the reptiles, the
amphibians, the bony fish and the agnathans. The serum of
Naha na'a kaouthia, the Indian cobra, can lyse mammalian
erythrocytes in the presence of Mg-EGTA but not in the
presence of EDTA (Vogel and Muller-Eberhard, 1985). In the
presence of Mg-EGTA, the hemolytic activity was greatest
against rabbit erythrocytes although, a low level of
activity could be detected against sheep erythrocytes. The
alternative pathway activators inulin, zymosan, and LPS,
were able to deplete cobra serum of its hemolytic activity
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indicating an alternative pathway of complement activation
in this species. The serum of five Japanese species of
snakes have been tested for lytic activity against sheep
erythrocytes (Kawaguchi et al., 1978). The degree of
hemolysis was seen to be dependent on the titre of natural
antibody to sheep cells, perhaps indicating a classical
pathway-like activation mechanism in the lysis of these
target erythrocytes. Koppenheffer (1986) reported the lysis
of rabbit erythrocytes by the serum of turtles, Psudemys
scripta, in the presence of magnesium alone. Sekizawa et
al. (1984) reported classical and alternative pathway
activity in the serum of clawed toads, Xenopus laevis. The
lysis of sheep erythrocyte targets by toad serum was found
to require both calcium and magnesium ions whereas the lysis
of rabbit erythrocytes required only magnesium.
Additionally, toad serum absorbed with sheep erythrocytes
did not lyse sheep cell targets indicating the need for toad
natural antibody for the lysis of sheep cell targets.
Alexander and Steiner (1985) isolated from the serum of
Rana catesbieans, the bullfrog, what appears to be the
bullfrog analog of classical complement pathway component
Cl. Cl from bullfrog serum can replace guinea pig Cl in
hemolytic assays using Cl-deficient guinea pig serum. A
comprehensive study of complement activity in the rainbow
trout, Salmo gairdneri, (Nonaka et al., 1981) demonstrated
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that lysis of sheep red blood cells by trout serum was
dependent on trout anti-sheep erythrocyte IgM and was
blocked by both EDTA and EGTA indicating a calcium-dependent
hemolytic system which requires antibody, thus resembling
the classical pathway of mammals. Alternatively, the lysis
of rabbit erythrocytes proceeded in the absence of calcium
ions and without trout anti-rabbit erythrocyte antibody
indicating the presence of alternative pathway activity.
Furthermore, incubation of trout serum with zymosan, LPS and
inulin depleted the serum of its hemolytic activity.
Functional assays of carp, Cy rinus carpio, complement
activity (Matsuyama et al., 1988) indicate both classical
and alternative pathway activity in this teleost fish.
Assay of carp serum for hemolytic activity, in the presence
of EGTA and magnesium ions showed a higher degree of lysis
of rabbit cells under these conditions than other target
cells. A low level of lytic activity however, did remain
against both sheep and bovine erythrocytes. Horse
erythrocyte targets were not used in this study. Jensen and
colleagues (Jensen et al.,1968; Jensen, 1969; Jensen et
al.,1973; Ross and Jensen, 1973; Jensen et al.,1981; Hyder-
Smith and Jensen, 1986) in an extended study of the
complement system of the nurse shark, Ginglymostoma
cirratum, were able to functionally isolate six components
which act sequentially to bring about the lysis of sheep
erythrocytes sensitized with nurse shark natural antibody.
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The lesions produced by shark complement on sheep
erythrocytes were indistinguishable from those produced by
mammalian complement (Jensen et al., 1981). The complement
system in the nurse shark is functionally analogous to the
classical pathway of mammals and no evidence for alternative
pathway activity in this species was presented. Results of
these studies have lead several reviewers to state that the
classical pathway of activation alone operates in sharks
(Koppenheffer, 1987; Day and Dodds, in press).
The serum of the lamprey, Lam etra japonica, one of the
most primitive of vertebrates, has been shown to strongly
promote phagocytosis (Nonaka et al., 1984). This activity
was attributed to a C3-like molecule which in the presence
of lamprey serum (source of other needed serum factors) and
divalent cations, bound to the surface of zymosan, a good
activator of the mammalian alternative pathway. The
activity of lamprey serum was thought to be due to an
alternative pathway-like system. This activity was also
sensitive to heat and to the presence of EDTA, two
characteristics essential for activity to be attributable to
complement. The lytic activity of lamprey serum against
rabbit erythrocytes did not meet these criteria and
therefore could not be attributed to complement (Gigli and
Austen, 1971).
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Studies in invertebrates have provided functional
evidence for the existence of complement-like activity in
these primitive animals (Gigli and Austen, 1971) Day et
al., (1970) found that cobra venom factor, an activator of
mammalian alternative complement pathway and an analog of
mammalian C3 which is not regulated by mammalian control
proteins, was able to induce the lysis of sheep erythrocytes
by the hemolymph of the horseshoe crab and sipunculid worm,
but not that of starfish. Recent studies on invertebrate
"complement" have concentrated on molecular rather than
functional evidence because of the difficulty in
interpretation of hemolytic assays in these animals. The
thiolester-containing protease inhibitor, alpha 2
macroglobulin, has been isolated from the hemolymph of the
horseshoe crab Limulus polyphemus (Quigley and Armstrong,
1985) and the american lobster Homarus americanus (Spycher
et al., 1987). As considerable homology exists between
alpha 2 macroglobulin and the thiolester containing proteins
of mammalian complement, C3 and C4, these proteins most
likely share a common evolutionary origin (Sottrup-Jensen et
al., 1985). Furthermore, alpha 2 macroglobulin is
considered to be the ancestral protein of this family of
proteins and from which the others arose (Reid, 1986a). The
presence of channel-forming proteins which are similar to
the terminal complement component C9 of mammals has been
established in invertebrates as well (Canicatti and Tschopp,
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1989). Molecular evidence, therefore indicates that at
least the potential exists for primitive complement
components to be present in invertebrates.
While functional activity of the complement systems of
many lower vertebrates and invertebrates has been described,
the information is by no means comprehensive. It is apparent
from the literature that the classical pathway of complement
activation exists in representatives of most vertebrate
classes; the alternative pathway though demonstrated in
representatives of some vertebrate classes, has not been
described in the cartilagineous fish. The question of
whether or not the alternative pathway is present in these
primitive vertebrates is an important one from an
evolutionary point of view. The alternative pathway does
not require specific antibody for activation and so may be
considered an innate defense mechanism (Roitt et al., 1985).
For this reason, the alternative pathway has been considered
to be the phylogenetically older of the two activation
pathways. Given that the classical pathway exists in the
nurse shark, if the alternative pathway is truly the
evolutionary predecessor of the classical then it is likely
to be present in the nurse shark. Recently it has been
found that a mammalian lectin, mannan binding protein (MBP),
specific for mannose and N acetylglucosamine, can activate
the classical pathway directly without the participation of
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Ciq (Ohta et al., 1990). This lectin has a gross structure
homologous to Clq and has been found to replace Clq as a
recognition unit and activator of Clr and C1s in lytic
assays employing C1q depleted serum. The acute phase
protein, C reactive protein (CRP), can also activate the
classical pathway by binding Cl when it is in complex with
the surface C polysaccharide of bacteria in the absence of
specific antibody. These observations provide a basis on
which it can be argued that the classical pathway could have
evolved prior to the specific antibody response and then
could be the phylogenetically older of the two pathways. A
molecule similar to CRP has been detected in the coelomic
fluid of the horseshoe crab which further supports this
possibility (Robey and Liu, 1981). Alternatively, in the
nurse shark especially, the large pool of natural antibodies
may make the alternative pathway of complement activation
redundant and therefore not evolutionarily advantageous.
Thus the question remains does or does not alternative
pathway activity exist in the nurse shark?
Functional and structural homologies between factor B
and C2, the serine proteases of the alternative and
classical pathway C3 convertases respectively, have been
described (Bentley and Campbell, 1986). Both are unusual
types of serine proteases in that their catalytic chains are
over twice the size of the catalytic chains of other serine
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proteases (Reid and Porter, 1981). Functionally, both
enzymes, within the C3 convertase complexes, cleave the
identical peptide bond between arginine 77 and serine 78 in
the alpha chain of C3 to form C3b and C3a. Within the C5
convertase complexes these enzymes also cleave at the
identical position in the C5 molecule to form C5b and C5a
(Reid, 1986). The genes coding for factor B and C2 are
closely linked (less than one kilobase apart) within the NHC
complex on human chromosome 6 (Volkanis, 1986) and therefore
are believed to have arisen through gene duplication, with
the gene for C2 arising from the factor B gene (Reid, 1986;
Farries, 1990). It would appear from this data that among
the serine proteases, the alternative pathway protein
(factor B) appeared before and is the ancestor of the
classical pathway protein (C2). However, among the
thiolester containing proteins, alpha 2 macroglobulin is
considered to be the ancestral protein from which the
complement proteins C3 and C4 have evolved. Therefore the
presence of alpha 2 macroglobulin in invertebrate species
yields no information as to which pathway may have evolved
before the other. It is obvious from these observations
that the phylogeny of complement evolution is no longer as
clear as previously believed. Comprehensive evaluation of
whether or not the alternative pathway is present in the
cartilagineous fish will provide additional information on
the origin of both pathways. The classical pathway has
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already been defined in a representative of this class of
vertebrates, the nurse shark. The alternative pathway
remains to be studied.
Ginglymostoma cirratum, the nurse shark is a primitive
cartilagineous fish belonging to the subclass
Elasmobranchii. This particular species of shark is
believed to have survived for 130 million years (Springer
and Gold, 1989). The classical pathway of complement
activation has been described in the nurse shark by Jensen
and colleagues (Jensen et al., 1981). These studies
indicate the nurse shark complement system consists of six
functionally purified components Cln, C2n, C3n, C4n, C8n and
C9n. Cln was shown to be functionally analogous to
mammalian C1 (Ross and Jensen, 1973). The cellular
intermediate EAnCln (sheep erythrocytes optimally sensitized
with nurse shark natural antibody to which Cln has been
fixed) could be lysed by guinea pig complement components
C4-C9 indicating C1n is capable of cleaving mammalian C4
and C2 in a manner similar to mammalian Cl. Furthermore,
Cln showed a single precipitin arc on immunoelectrophoresis
against either anti-Cln antisera or antiserum to whole shark
serum. In the presence of EDTA, a chelator of metal ions,
however, three precipitin arcs could be demonstrated. These
results indicated Cln to be a complex of subcomponents whose
integrity depends on metal ions, a feature characteristic of
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mammalian C1. One difference between mammalian C1 and nurse
shark C1n was in the reversibility of the dissociation of
subcomponents in the presence of EDTA by the addition of
calcium, magnesium or other metal ions. Whereas the
subcomponents of Cl could, after chelation, reassociate to
form a functional molecule on the addition of divalent ions,
the Cln complex is unable to reassociate (Ross and Jensen,
1973), possibly due to an irreversible conformational change
in one or more of the subcomponents. Shark Cln however, was
found to be more resistant to inactivation by EDTA than
guinea pig C1 but only at 000. At 500 or higher
temperatures both shark and guinea pig Cl were rapidly
inactivated by EDTA. These results clearly demonstrated a
requirement for metal cations for the activity of Cln.
Studies also indicate a functional similarity between C2n of
nurse shark and mammalian C4 (Hyder-Smith and Jensen, 1986).
Similarly, C8n and C9n are comparable to the terminal
components of the mammalian system Jensen et al., 1973).
Because functional analogies exist, it has been possible to
perform hemolytic assays on nurse shark serum using
mammalian erythrocyte targets and employing metal ion
chelators to evaluate the complement activity of nurse shark
serum. The purpose of this study was to determine whether
alternative pathway activity could be demonstrated in nurse
shark serum using conventional criteria previously
established to successfully demonstrate and confirm
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alternative pathway activity in other vertebrate classes
including ectotherms.
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MATERIALS AND METHODS
Nurse Shark Serum
Nurse shark serum was obtained from animals of
various sizes, both male and female, held in open sea water
pens at the Keys Marine Laboratory on Long Key, Florida.
Sharks were anesthetized by being placed in sea water
containing 1 ppm tricaine methane sulfonate and subsequently
bled from the caudal vein. Once bled, sharks were revived
by passing sea water over their gills until gill activity
was observed and normal swimming movement could be detected.
Temperature of the water in the pen was noted and recorded
at the time of each collection. Whole shark blood was
placed on ice and transported to the laboratory where it was
allowed to clot overnight at 40C. Serum was then separated
by centrifugation at 2000 x g and 40C. Serum was stored at
00C in a circulating water bath until assays were performed.
Collection data is given in appendix 1.
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Chemicals and Reagents
The sources of chemicals and reagents used in this
study are indicated in appendix 2. All water used in the
preparation of reagents and buffers was doubly distilled
water.
Buffers and Solutions
I. Stock solutions:
5 X Veronal was prepared by dissolving 42.5g sodium
chloride, 1.875g sodium Barbital and 2.875g Barbituric acid
derivative in one liter of water. Barbituric acid
derivative was first dissolved in about 200 ml of hot water.
Sodium barbital and sodium chloride were dissolved in water
at room temperature. When the Barbituric acid derivative
was completely dissolved this solution was added to the
barbital/sodium chloride solution at room temperature. The
pH of the resulting solution was then adjusted to 7.4 with 1
N NaOH. Once the pH was adjusted, the solution was
transferred to a one liter volumetric flask and the volume
was adjusted with water. 5 X Veronal was stored at 40C
until needed (Campbell et al., 1968).
5% Dextrose (w/v) was prepared by dissolving 50g of
dextrose in 1000 ml of water. This solution was aliquoted
into 250 ml portions and autoclaved at 1210C, 15 pounds of
pressure for 10 minutes and stored at 40C until required.
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2% Gelatin (w/v) was prepared by dissolving 4g of
gelatin in 200 ml of water with gentle heating until the
gelatin was completely in solution. This solution was
aliguoted into 25 ml amounts and autoclaved at 1210C, 15
pounds of pressure for 15 minutes.
A 0.1 M stock solution of magnesium was prepared by
dissolving 2.033g of magnesium chloride in 100 ml of water.
A 0.03 N stock solution of calcium was prepared by
dissolving 1.11g of calcium chloride in 100 ml of water.
Stock solutions of divalent cations were not autoclaved but
were stored at 40C.
0.1 N stock solutions of chelators were prepared by
dissolving 39.04g ethyleneglycol-bis-(beta-amino ethyl
ether) N,N,N,N-tetra acetic acid (EGTA) or 29.22g
ethylenediaminetetra acetic acid (EDTA) in a final volume of
one liter of water. Neither chelator will dissolve
completely in the acidic conditions produced when these
compounds are added to water, thus the pH had to be
increased to approximately neutral by the addition of 10 N
NaOH until the chelator was completely dissolved. The
chelator solution was then transferred to a one liter
volumetric flask and the volume adjusted with water.
All stock solutions were stored at 40C until needed.
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II, WorkingBuffers:
Dextrose Gelatin Veronal buffer (DGVB) was prepared
fresh daily in 500 ml amounts by adding 100 ml of 5 X
Veronal, 25 ml of 2% gelatin and 125 ml of water to 250 ml
of 5% dextrose. This solution was used for target
erythrocyte preparation.
Dextrose Gelatin Veronal with calcium and magnesium
(DGVB++) was prepared as above except 2.5 ml of 0.1 N NgCl2
and 2.5 ml of 0.03 M Cadl2 was added in place of 5 ml of
water to give a final concentration of 0.15 mM Calcium and
0.5 mM Magnesium. The pH of these buffers was 7.4.
Chelating buffers were prepared in 100 ml aliquots by
adding various amounts of 0.1 N stock chelator solution to
20 ml 5 X Veronal and 5 ml 2% gelatin. The pH was adjusted
to 7.4 with 1 N NaOH and the solution was brought up to 100
ml with water. The exact composition of the various
chelating buffers is given in appendix 3.
Chelating buffers containing magnesium were also
prepared in 100 ml aliquots by adding various amounts of 0.1
N MgCl 2 to 20 ml 5 X Veronal, 5 ml 2% gelatin and 20 ml 0.1
N EGTA or 0.1 N EDTA. The solution was adjusted to pH 7.4
with 1 N NaOH and brought up to 100 ml with water. The
exact composition of the various chelating buffers with
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added magnesium is given in appendix 4.
EDTA saline was used in agglutination assays for the
determination of natural antibody titre of nurse shark serum
to target erythrocytes. 100 ml aliquots were prepared by
adding 20 ml 0.1 N EDTA stock solution to 80 ml
physiological saline (0.15 M NaCl, ACS grade).
III. Solutions for immunoblottin porocedures:
Dot Blots:
A concentrated stock solution of Tris buffered saline
(TBS) was provided in a commercially available immunoblot
assay kit (BioRad Immun-Blot Assay kit, Richmond, CA). Once
diluted to working strength this buffer contained 20 mM
Tris-HCl and 500 mM NaCl in water at pH 7.5.
Tween 20 wash solution was prepared from working
strength Tris buffered saline by adding Tween 20 to give a
final concentration of 0.05% Tween 20 in TBS (TTBS).
Antibody buffer was prepared by dissolving enough
bovine serum albumin, BSA, (Sigma, St Louis, NO) in TTBS
described above to give a final concentration of 1% BSA.
Blocking solution used in this assay was prepared by
dissolving enough bovine serum albumin in Tris buffered
saline described above to give a 1% solution.
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Western blots:
Western blots were performed using a multiscreen
apparatus (BioRad, Richmond, CA) and by conventional means.
Shark and human serum at 1:5 dilution were electrophoresed
on 7.5% sodium dodecyl sulfate polyacrylamide gels (SDS-PAGE
gels). Resolving gel for two gels was prepared by mixing 9.7
ml distilled water with 5.0 ml of 1.5 N Tris-H l, 5.0 ml of
Acrylamide/Bis (30%T, 2.67%C prepared by dissolving 29.2g
Acrylamide and 0.8g Bis acrylamide in 100 ml water) and 200
ul of 10% SDS. This solution was degassed under vacuum for
15 minutes after which time the polymerizing agents, 100 ul
freshly prepared 10% ammonium persulfate and 100 ul of
TEMED were added. This monomer solution was then used to
fill glass plate "sandwiches"(assembly is described in
BioRad Mini-PROTEAN II multi-casting chamber manual and
Mini-PROTEAN II dual slab cell manual for single gel
casting) up to about one centimeter from the top of the
small glass plate. Gel casting "sandwiches" contained 1 mm
spacers between the two glass plates to produce 1 mm thick
gels. Gels were then overlayed with water saturated amyl
alcohol and allowed to polymerize for one hour. When the
resolving gel was polymerized, the amyl alcohol was poured
off and the top of the gels were rinsed with distilled water
and completely drained. The stacking gel mixture described
below was poured onto the top of the resolving gel. Teflon
combs were placed into the glass plate "sandwich" prior to
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pouring the stacking gel. For Western blots, a preparative
comb (one large broad well and one small narrow standard
well) was used. For other routine SDS PAGE applications,
combs for 10 wells were used. The stacking gel was prepared
by mixing 12.2 ml of distilled water with 5.0 ml of 0.5 M
Tris-HCl 2.6 ml of Acrylamide/Bis (described above for
resolving gel) and 200 ul of 10% SDS. This solution was
degassed under vacuum for 15 minutes after which 100 ul of
10% ammonium persulfate and 20 ul TEMED were added. The
stacking gel was allowed to polymerize for one hour at room
temperature and the gels along with inserted combs were
stored in sealed plastic bags with a small amount of
electrode buffer at 40C in a glass jar until used.
A 5 X solution of electrode buffer, used to dilute
samples and run electrophoresis, was prepared by dissolving
4.5g of Tris base, 21.6g of glycine and 1.5g of SDS to a
final volume of 300 ml in water.
Sample buffer for electrophoresis was prepared by
adding 1.0 ml 0.5 M Tris HCl, 0.8 ml glycerol, 0.2 ml 0.05%
bromophenol blue and 1.6 ml 10% SDS to 4.0 ml distilled
water. For reducing samples prior to electrophoresis 0.4 ml
of 2-mercaptoethanol was added to the buffer and samples
were heated at 950C for 4 minutes.
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Transfer buffer, for the transfer of proteins from the
electrophoresis gel to the nitrocellulose membrane, was
prepared by dissolving 3.03g Tris base and 14.4g glycine in
approximately 800 ml of water. 200 ml of methanol
(analytical reagent grade) is then added. The pH should be
approximately 8.3 and it should not need to be adjusted.
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Target cells
I. Preparation of cell suspensions:
Sheep, bovine, horse and rabbit whole blood in
Alsever's solution was obtained from Lampire Biological
Laboratories, Pipersville, PA. An aliquot of whole blood
suspension (usually 10 ml) was washed three times in 30-40
ml of chilled (40C) isotonic saline (O.15 M NaCl, ACS grade)
in 40 or 50 ml round bottom glass centrifuge tubes. In a
Beckman refrigerated Gpr centrifuge equilibrated at 40C the
cell suspension was centrifuged at 1000 x g for 15 minutes.
The buffy coat was removed from the sedimented cells using a
wide tip pasteur pipet after the first wash. Following the
saline washes, the cells were washed two more times in DGVB
without calcium or magnesium (DGVB--) and resuspended in
this buffer. Washed cells were then standardized to a
concentration of 1 X 109 cells/ ml and stored for up to one
week at 00C in either a circulating water bath or on ice in
styrofoam coolers.
TI. Standardization of target erythrocytes:
Standardized erythrocytes suspensions were prepared
from washed erythrocyte stock suspensions. An aliquot of
these cells was resuspended in a measured volume of DGVB--.
The cells per milliliter of suspension was determined
manually using a hemocytometer (Reichert Scientific
Instruments, Buffalo, NY) or by an automated method using a
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Coulter counter (Coulter Corporation, Hialeah,FL).
Depending on the counts obtained, the volume of DGVB-- was
adjusted to yield a 1 X 109 cells/ml stock suspension.
Stock cell suspensions were stored for up to one week at
00C. For use in assays, the stock cell suspensions were
diluted to 1 X l08cells/ml in buffer. Prior to dilution,
the stock cell suspensions were washed twice in DGVB--. An
optional optical method that was easier to perform and more
rapid was also employed to standardize cell suspensions.
For each new lot number and cell type received, a manual
count was performed to standardize a suspension to 1 X
1 8cells/ml. One ml of this suspension was lysed in a total
volume of 15 ml of distilled water in a volumetric flask.
The optical density of the solution was determined at 415 nm
in a Beckman DU-68 spectrophotometer. The optical density
value obtained is the OD factor in the equation:
Vf = Vx OD/F, used to standardize cells to a
concentration of 1 X 108. Vf is the final volume, Vi is the
initial volume and F is the optical density factor
determined for the erythrocyte suspension of a particular
species and lot number (Campbell et al., 1968). The CD
factor (F) was established for each erythrocyte species and
each fresh erythrocyte lot number received.
III. Preparation of sensitized erythrocytes:
Nurse shark natural antibody was used to sensitize
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sheep and bovine target erythrocytes. The source of nurse
shark natural antibody was heat-inactivated (56'C, 30 min)
nurse shark serum. One volume of a 1 X 10 9cells/ml
suspension of erythrocytes was mixed with the same volume of
a subagglutinating dilution (determined by agglutination
assay, see below) of heat-inactivated nurse shark serum in
DGVB--. The cell suspension was incubated in a shaking
water bath at 370C for 30 minutes and then at 0oC for an
additional 30 minutes with manual shaking at 5 minute
intervals. The suspension was incubated in small flasks
rather than tubes to ensure maximum exposure of the cell
surfaces to antibody and to allow adequate mixing and
therefore better sensitization. Following incubation cells
were washed twice in DGVB-- to remove excess antibody and
restandardized to 1 X 109 cells/ml and stored at 0 C for up
to three days (Jensen, 1969).
Preparation of alternative pathwa activators
Activators used in this study were zymosan, inulin,
cobra venom factor (CVF) and lipopolysaccharide (LPS).
Zymosan was prepared by suspending 400 mg of zymosan in 100
ml physiological saline and boiling for two hours, adding
additional saline as needed (Fine et al., 1972). The
zymosan particles were washed twice in saline and
resuspended in 20 ml saline to a final concentration of 20
mg zymosan/ml. Lyophilized lipopolysaccharide from
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Salmonella tyhosa (Sigma, St Louis, MO) in 100 mg aliquots
was resuspended with 5 ml of saline to a final concentration
of 20 mg LPS/ml. Inulin from dahlia tubers (Sigma) was
dissolved in saline to yield a stock solution of 20 mg
inulin/ml. One milligram of cobra venom factor from the
Indian cobra, Naia naia kaouthia, (Sigma St Louis, NO) was
reconstituted with 1 ml of saline. This solution was then
used in activation assays as a 1 mg/ml stock.
Agglutination assays
Agglutination assays were performed on nurse shark
serum in order to determine the titre of natural antibodies
to the target erythrocytes used. The assays were set up in
"U" bottom polyvinyl microtitre plates (Dynatech, Chantilly,
VA) using a four drop system (Ross and Jensen, 1973).
Doubling dilutions of nurse shark serum were prepared by
adding one drop (25 ul) of serum to one drop of EDTA-saline
and serially diluting the serum with microdiluters. Two
drops of EDTA-saline were then added to each well followed
by one drop of 1 X lOScells/ml suspension of target
erythrocytes. Negative controls contained three drops of
EDTA-saline and one drop of target erythrocytes with no
serum. Plates were incubated at 300C for 15 minutes with
shaking on microtitre shakers and then left at room
temperature for several hours to allow the cells to settle
or alternatively kept overnight at 400. Agglutination was
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determined by comparing the behavior of the cell buttons to
the control as plates are tilted at about a 450 angle to
allow the buttons to run. Agglutination titre was recorded
as the reciprocal of the highest dilution showing
agglutination.
Hemolytic assays
Hemolytic assays were performed in "VY' bottom polyvinyl
microtitre plates (Dynatech, Chantilly, VA) using a five
drop assay. Doubling dilutions of shark serum were made by
adding one drop (25 ul) serum to one drop of buffer (DGVB++,
EDTA/EGTA-GVB or EDTA/EGTA-GVB-Mg++) and serially diluting
the serum with microdilutors. Three drops of buffer were
then added to each well followed by one drop of 1 X
10 8cells/ml target erythrocytes. Spontaneous lysis controls
consisted of one drop of cells in four drops of buffer.
100% lysis controls consisted of one drop of cells in four
drops of distilled water. All buffers and target cell
suspensions as well as serum were kept on ice while the
assays were being set up so that no activation of complement
occurred prior to incubation. Plates were incubated at 300C
with shaking on microtitre shakers for one hour. After this
incubation period the plates were centrifuged at 500 x g to
stop the hemolytic activity and the reciprocal of the last
dilution showing 50% lysis was determined as the hemolytic
titre. Determination of this end point was made visually by
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comparison to the spontaneous lysis control (Jensen and
Ross, 1973). The plates were then stored overnight at 40C
and read again the next day as results became clearer and
easier to interpret after this time period.
Determination of the effect of chelators on the hemolytic
activity of nurse shark serum
I. Incubation time of serum in the presence of chelator:
Rapid fixation of C1, 04 and C2 occurs in human serum
before C1 is inactivated by removal of calcium in the
presence of EGTA (Platts-Nills and Ishizaka, 1974). The
fixation of shark Cln has also been shown to occur within 5
minutes even at OOC (Ross and Jensen, 1973); thus it is
necessary to incubate shark serum in the presence of the
chelator to allow complete binding and removal of calcium
and or magnesium prior to performing hemolytic assays. To
determine the optimum period of time necessary for removal
of divalent cations from nurse shark serum by the chelators,
assays were set up as described above in buffers containing
chelators except for the target cells which were not added.
Plates were incubated for periods of 15, 30 and 45 minutes
at 300C without shaking before the addition of target cells.
After target cells were added plates were incubated for one
hour at 300C with shaking in microtitre shakers. The
endpoint was read as described above. The effect of
incubation at higher temperature (300C) on complement
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components was evaluated by assaying the serum under
identical conditions in the absence of the chelator for loss
of activity.
II. Amount of chelator needed to remove calcium and or
magnesium from nurse shark serum:*
Normal values for serum calcium and magnesium levels
have not been established in the nurse shark, however, a
study conducted by Keys Marine Lab in which sharks were
caught and tested for several blood chemistries revealed
that calcium values for the eleven nurse sharks tested
ranged from 12.1 to 16.5 mg/dL. Using 14 mg/dL as an
average value mg/dL was converted to 3.5 mmol calcium. Only
two of the nurse sharks in this study were tested for
magnesium levels. Magnesium values were 2.6 and 3.5 meq/L
which would convert to 1.3 mmol/L and 1.75 mmol/L
respectively (Murru, 1984). With a limited amount of
previous information available for estimating how much
chelator would be required to remove these divalent cations
from the serum of sharks, assays were conducted using
varying amounts of chelators to establish this parameter.
Hemolytic assays were set up as described above using
buffers containing varying amounts of chelator. The
composition of these buffers are given in appendix 3. The
serum was chelated by incubating the plates without shaking
for the optimal time established from the procedure outlined
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above before the addition of target cells. After the
addition of target cells the plates were incubated at 300C
for one hour with shaking. The endpoint was again read as
above. To determine the effect of EGTA, in concentrations
ranging from 5 to 25 mM, on a larger number of individual
sera, an alternative procedure was developed. In this
procedure shark serum was mixed with various amounts of 0.1
N stock EGTA solution, 0.1 N stock EDTA solution or DGVB++
and incubated at 3Q 0 C for 30 minutes previously established
as optimal time and then assayed for hemolytic activity.
The various amounts of shark serum and chelators are given
in appendix 4. Chelated serum was then used in hemolytic
assays, as described above, using buffers containing an
equivalent amount of chelator.
III. Determination of the effect of added magnesium on the
hemolytic activity of chelated nurse shark serum:
Nurse shark serum was chelated as described above with
20 mn EGTA. The hemolytic activity of serum was evaluated
by conducting microtitre assays in buffers containing 20 mM
EGTA and increasing amounts of magnesium ions. The
composition of these buffers are described in appendix 5.
The addition of magnesium ions to a solution containing EGTA
or EDTA results in a drop in pH of the solution (Platts-
Mills and Ishizaka, 1974). Complement activity as well as
stability of target cells is profoundly affected by pH
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(Kabat and Mayer, 1961). Therefore, to obtain meaningful
comparative data on hemolytic activity as a function of
magnesium ion concentration the pH of all buffers used in
these experiments was adjusted to 7.4 with 1 N NaOH before
the volume was adjusted to 100 ml with distilled water.
Determination of the effect of activators of the mammalian
alternative pathway on the hemolytic activity of nurse shark
serum
No information is available on the amount of
alternative pathway activators needed to deplete nurse shark
serum of hemolytic activity. Therefore, various amounts of
activators were used ranging from 1 to 10 mg/ml suspensions
for zymosan, LPS and inulin and 0.05-0.25 mg/ml suspensions
for cobra venom factor. Activation assays were set up in 30
ml round bottom glass centrifuge tubes.
Stock suspensions of activators were prepared as
described and various quantities added to the reaction
tubes. The volume in each tube was then brought up to one
ml as necessary by the addition of buffer (DGVB++ or 20 mM
EGTA-10 mM Mg++-GVB). Exact ratio of buffer to stock
activator is given in appendix 6. One ml of shark serum was
then added to each tube and incubated at 300C in a shaking
water bath. A sufficient number of tubes were set up so
that one complete set (containing 0, 1, 5 and 10 mg/ml
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activator) could be removed at zero time, 90 minutes, three
hours, 4.5 hours and overnight as the protocol required.
Once removed from incubation these tubes were centrifuged
and kept at 0 0C until residual hemolytic activity was
determined by microtitre assay as described previously.
Immunobl otting
The presence in nurse shark serum of complement
proteins which would antigenically cross react with antisera
raised against human complement components was investigated
using immunoblotting techniques.
I. Dot blots:
Dot blots were performed using both the Ninifold
(Schleicher and Schuell, Keene, NH) and Biodot (BioRad,
Richmond, CA) dot blotting manifolds. Nitrocellulose
membranes were prepared for the procedure by wetting in Tris
buffered saline (TBS). Wet membranes were then placed in
the dot vacuum manifold and each well was wetted again with
100 ul of TBS. 100 ul of each diluted serum sample to be
tested was then placed in each well of the dot blot
template. Dilutions of nurse shark serum were prepared in
TBS to yield 1:10, 1:100 and 1:200 dilutions. Human and
guinea pig serum as well as lysozyme (65 units/ml), were
prepared in a similar manner to yield dilutions of 1:100 and
1:200. Serum and control samples were allowed to flow
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through the membrane by gravity. When the entire sample had
passed through the membrane, it was washed with 100 ul TBS
per well. Unreacted sites on the membrane were then blocked
using 300 ul per well of a 3% bovine serum albumin blocking
solution. The blocking solution was left on the membrane
for one hour and then the membrane was washed twice with 200
ul Tris buffered saline with Tween 20 (TTBS) using a vacumn.
100 ul of diluted primary antibody (1:15 or 1:30 in antibody
buffer) was then added to the appropriate wells. The
primary antibody solutions were allowed to drain through the
membrane by gravity. Once the primary antibody solutions
had passed through, the membrane was washed three times with
300 ul TTBS per well. Following the last wash, 100 ul of
diluted secondary antibody labelled with horse radish
peroxidase was added to each well and allowed to drain
through by gravity. After the secondary antibody had
drained through, the membrane was washed twice with 300 ul
TTBS per well. The membrane was then removed from the
manifold and washed twice in TBS. The blot was then
developed following the directions of the BioRad ImmunoBlot
Assay kit until good contrast was developed between the
control and samples. Color development was stopped by
placing the membrane in distilled water.
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II. Western Blots:
Human and shark serum were diluted 1:5 in electrode
buffer and then 1:4 in sample buffer. These samples were
heated at 950C for 4 minutes before loading SDS-PAGE gels
(Laemmli, 1970) for electrophoresis. Electrophoresis was
conducted using the BioRad Mini-Protean II dual slab cell at
200 volts. Electrophoresis was discontinued when the
tracking dye reached the end of the gel which took
approximately 45 minutes. Runs using gels cast with
preparative combs (for use in the multiscreen apparatus)
were loaded with 1500 ul of sample diluted 1:4 in sample
buffer and heated as described. Five ul of a prestained low
molecular weight standard mixture (BioRad, RichmondCA) was
loaded in the small well of the preparative gel directly
without the dilution and preparation described above. Ten
microliters of sample and 10 ul of a prestained molecular
weight standard (BioRad, Richmond CA) was loaded into wells
when using gels cast with ten well combs. Once
electrophoresis was complete, the gels were removed and
equilibrated in 500 ml of transfer buffer for 15 minutes.
The BioRad Mini transblot apparatus was used to
electrophoretically transfer proteins from the
polyacrylamide gel to the nitrocellulose membrane for
immunoblotting (Towbin et al., 1979). The membrane was
first wetted in transfer buffer before assembling the
gel/membrane sandwich. The electrophoretic transfer was
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conducted at 70 V for one hour. Following transfer,
unreacted sites on the membrane were blocked by incubation
in 1% BSA for one hour at room temperature and then rinsed
in TBS. At this point, if the multiscreen apparatus was to
be used the membrane was placed inside the apparatus and it
was assembled. Primary antibody, 600 ul, was added to a
single channel of the multiscreen. Multiple antisera could
be screened simultaneously against a single serum sample
using the multiscreen apparatus. For Western blots using a
single antisera, the membrane was flooded with 6 ml of
primary antisera in a large shallow weigh boat. For both
procedures, the membrane was incubated at room temperature
with the primary antibody for one hour. Following this
incubation period, the membrane was washed three times in
TTBS and the secondary antibody was applied. Secondary
antisera was applied to each individual channel of the
multiscreen (600 ul) or the entire membrane was submerged in
antiserum (6 ml) in a weigh boat. The secondary antibody
was allowed to incubate on the membrane for one hour at room
temperature. Following this incubation the membrane was
washed five times with TTBS and then in TBS for 5 minutes.
The blot was developed using a BioRad color development kit
as described above, Description and sources of primary and
secondary antibodies used in immunoblotting are given in
appendix 7.
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RESULTS
Acgglutination assays:_
Results of agglutination assays are given in table 1.
These results indicate a high level of natural antibody in
nurse shark serum against rabbit cells, moderate levels of
antibody to sheep and horse erythrocytes and a minimal level
against bovine erythrocytes. These levels of natural
antibody were demonstrable consistently in all nurse shark
sera tested.
Effect of chelators on the hemolytic activity of nurse shark
serum
I. Incubation time of serum in the presence of chelator:
Table 2 show the results of hemolytic assays in which
nurse shark serum was incubated with various concentrations
of EDTA for several different periods of time, prior to
assaying for residual activity. These results represent
experiments on a single individual. Complete inhibition of
hemolytic activity was seen against sensitized sheep and
unsensitized horse erythrocyte target cells when serum was
chelated with 5 mM EDTA for 30 minutes. Some reduction in
the hemolytic titre of the serum control (containing no
chelator) was seen against horse erythrocytes when the serum
was preincubated for 45 minutes. From these experiments
with sheep and horse erythrocytes it was determined that in
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order to demonstrated depletion of hemolytic activity of the
serum preincubation of the serum with the chelator was
necessary for chelators to bind the metal cations present in
nurse shark serum. The 45 minute preincubation time which
resulted in a decrease in lytic activity, is most likely due
to a spontaneous deterioration of one or more complement
components, against at least one target cell. Therefore,
time periods of 15 and 30 minutes were chosen to be near
optimal for chelation of serum prior to assaying hemolytic
activity against rabbit cells. Results for rabbit cell
targets, given in table 3, demonstrate a preincubation
period of 30 minutes, in the presence of 10 mM EDTA is
necessary to completely prevent lysis of rabbit erythrocytes
by nurse shark complement. Experiments were then conducted
with sensitized and unsensitized bovine erythrocytes as
targets, using nurse shark serum preincubated with varying
amounts of EDTA for 30 minutes. Results, presented in table
4, show that there is a complete loss of hemolytic activity
of nurse shark serum against bovine erythrocyte targets when
the serum is preincubated for 30 minutes. From these
chelation studies it was determined that serum hemolytic
activity against bovine, sheep, horse and rabbit
erythrocytes could be depleted by preincubation for 30
minutes in the presence of 10 mM EDTA without incurring
spontaneous reduction of lytic activity from inactivation of
complement components at the higher than ambient temperature
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(i.e. 300C). Following the experiments employing EDTA,
similar experiments were conducted using EGTA as the
chelator. At this point in the study results suggested that
a preincubation period was necessary for the chelator to be
effective in removing metal ions and thereby decreasing
hemolytic activity of the serum. Data also suggested that a
45 minute preincubation time at 30 0C may result in
spontaneous loss of hemolytic activity not due to the
chelator. Therefore, for studies investigating the effect
of EGTA, serum was preincubated for periods of 15 and 30
minutes only, in the presence of various concentrations of
the chelator. From the results of these experiments,
presented in table 5, it was concluded that 30 minutes was
sufficient preincubation time to allow EGTA to chelate nurse
shark serum without spontaneous loss of hemolytic activity.
The purpose of chelation experiments was to establish a
general protocol for chelating nurse shark serum in order to
assess the effect of chelators on the hemolytic activity of
the serum. Although these experiments were limited in
number of animals tested, it could be concluded that a 30
minute preincubation time in the presence of the chelator
does allow maximal activity of the chelator without
concomitant loss of serum hemolytic activity as a result of
factors other than the effect of the chelator.
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II, Concentration of chelator needed to remove cations from
nurse shark serum:
Results of the above experiments demonstrate that a
concentration of 10 mM EDTA, preincubated with serum for 30
minutes was sufficient to inhibit lysis of target cells by
nurse shark complement. Table 6a provides data on the
residual hemolytic activity of serum from several
individuals in the presence of 10 mM EDTA. These data
demonstrate that, for the great majority of nurse shark
serum/target cell combinations, 10 mM EDTA is sufficient to
completely inhibit hemolytic activity of whole nurse shark
complement. With a 30 minute preincubation time established
as being optimal for both EDTA and EGTA to completely
chelate metal cations from nurse shark serum, it was then
necessary to determine the concentration of EGTA which would
maximally inhibit lysis of target cells by nurse shark
complement. Table 6 presents the results of an experiment
employing serum from a single individual chelated with
increasing concentrations of EGTA to assess hemolytic
activity of such treated serum against the mammalian
erythrocyte targets. These data demonstrate no further
reduction of hemolytic activity against any target cell at
concentrations of EGTA greater than 10 mM. Concentrations
of EGTA above 25 mM were not considered to be useful and
therefore concentrations ranging from 5-25 mM were
reevaluated using serum from several individual animals.
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Hemolytic titres from these experiments are presented in
table 7. Absolute hemolytic titres for this set of
experiments were then converted to percent of the control
titre (containing no chelator) in order to better illustrate
and compare the phenomenon of loss of hemolytic activity due
to the chelator in serum samples which had differing initial
hemolytic titres. These data are presented in table 8.
Figure 1 presents these data in graphic form.
Statistical analysis of the data presented in table 8
is given in table 9. From the data presented in tables 6,7
and 8, and figure 1 it can be seen that although the
presence of EGTA significantly reduces the hemolytic titre,
nurse shark serum retains a low level of hemolytic activity
against all the mammalian target cells tested in the
presence of the chelator. As EGTA selectively chelates
calcium, it may be concluded that all available calcium ions
had been removed from the serum, and the hemolytic activity
that remained was totally independent of calcium ions.
Calcium independent hemolytic activity is considered to be
characteristic of the alternative complement pathway
specifically.
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The effect of added ma nesium ions onth hemolytic activity
of chelated nurse shark serum
As the alternative pathway requires magnesium ions, it
was necessary to determine the effect of added magnesium on
chelated serum. On the addition of magnesium ions to
chelated serum an increase in hemolytic activity due to
enhancement of the alternative pathway, if it operates in
the nurse shark, could be expected. The effect of added
magnesium, in concentrations ranging from 1-20 mM on the
hemolytic activity of shark serum chelated with 20 mM EGTA
is presented in table 10. In order to more clearly
demonstrate the reconstitution of hemolytic activity by the
addition of magnesium, the absolute hemolytic titres were
converted to percent of an unchelated control titre of the
same serum sample. Table 11 presents these data. The data
in table 11 is presented graphically in figure 2. From the
data in tables 10, 11 and 12, and figure 2 it was concluded
that 10 mM Mg++ added to nurse shark serum chelated with 20
mM EGTA would yield maximum hemolytic activity in such
serum. A significant level of hemolytic activity was seen
against both sensitized and unsensitized sheep erythrocytes;
this was unexpected as sheep erythrocytes are not lysed by
the alternative pathway of mammals (Platts-Mills and
Ishizaka, 1974). To confirm that the lysis of sheep
erythrocytes observed in these experiments was due to the
alternative pathway, nurse shark serum was chelated with 10
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mM EDTA and hemolytic assays were performed using 10 mM
EDTA-10 mM Mg++-GVB as the assay buffer. The chelated serum
was assayed for residual hemolytic activity as described
above against sensitized and unsensitized sheep erythrocytes
as well as sensitized bovine erythrocytes. The results are
recorded in table 12. From the data it can be concluded
that a calcium-independent hemolytic system that is also
magnesium dependent is responsible for the lytic activity
observed in nurse shark serum. Thus, the parameters for
demonstrating this alternative hemolytic system were
established as serum chelated with 20 mM EGTA to which 10 mM
Mg++ is added. Once it had been established that a calcium-
independent pathway (i.e. the alternative pathway) existed
in the nurse shark, it was of interest to determine if the
300C optimum temperature established by Jensen for the
classical pathway in the nurse shark was also optimal for
the alternative pathway as immune responses of ectotherms
have been shown to be temperature-dependent (Jurd, 1983;
Pettey and McKinney, 1983). Assays for total hemolytic
activity (in DGVB++) and alternative pathway activity (20 mM
EGTA-l0 mM Mg++-GVB) were performed on nurse shark serum
samples at different temperatures and the hemolytic titre
recorded. These results are presented in table 13 and show
that total hemolytic activity against sheep erythrocytes is
best demonstrated at 300C similar to the optimal temperature
for classical pathway as stated by Jensen (1981). The data
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from these experiments though limited, did suggest,
specifically when horse erythrocytes were used as targets,
that incubation at 2300 might yield higher alternative
pathway hemolytic titres and therefore be the optimal
temperature for demonstrating this activity. Consequently,
sera from several individuals were evaluated for alternative
pathway hemolytic activity at 2300 and 30CC using horse and
rabbit erythrocytes targets. Results are presented in table
13a. No increased levels of hemolytic activity against
these target cells was observed at 2300 when compared to
levels obtained at 3000, Additional data on a larger number
of animals and a wider temperature range are needed to
determine the temperature optimum for alternative pathway
activity in the nurse shark. For the purposes of this
study, based on the above observations, all subsequent
hemolytic titrations and activation of serum were carried
out at 3 0C.
The possibility was considered that the rate of the
alternative pathway activity might be slower than observed
for total hemolytic activity. Hemolytic assays were set up,
using horse erythrocytes as targets, in which incubation
time for the assays was increased from one to four hours,
Results are given in table 14. For the two serum samples
tested no increase in alternative pathway activity was
observed at either incubation temperature (230C or 300C) as
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incubation times were increased from one to four hours. In
addition, spontaneous lysis of the target cells in control
samples were a problem of increased incubation time.
Result from earlier experiments, employing selective
chelators to remove calcium ions from nurse shark serum
demonstrated a calcium-independent hemolytic pathway which
was enhanced by the addition of magnesium ions, i.e. an
alternative pathway of complement activation. To further
study and examine alternative pathway activity in nurse
shark serum it was necessary evaluate the ability of known
activators of the mammalian alternative pathway to activate
and in turn deplete the hemolytic activity of nurse shark
serum. Table 15 gives data on the depletion of hemolytic
activity, of both chelated (20 mM EGTA) and unchelated nurse
shark serum following incubation with increasing
concentrations of zymosan for various time periods at 300C.
The hemolytic titres obtained were converted to percent of
control samples (controls were nurse shark serum incubated
for the same time period with buffer containing no
activator) and presented as a bar graph in figures 3 and 4.
Table 16 shows the results of a similar experiment using LPS
as the activator in place of zymosan. Hemolytic titres, as
before were converted to percent of controls and plotted as
a bar graph in figure 5. Table 17 and 18 contain data from
experiments using cobra venom factor and inulin respectively
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as activators. Cobra venom factor and inulin did not
produce any significant reduction of hemolytic activity of
nurse shark serum under our experimental conditions.
Therefore, zymosan and LPS were selected as activators for
further studies using additional sera. Results of these
studies are presented in tables 19, 20 and 21, and in figure
6. Serum from one animal, tag# 463 showed a depletion of
hemolytic activity with increasing concentrations of zymosan
and incubation times for both unchelated or chelated (20 mM
EGTA) serum samples. Serum from the second animal (tag#
456), however, demonstrated a reduction of hemolytic
activity on incubation with and activation by zymosan only
when nonchelated serum was used. Chelated serum from this
individual did not show a loss of activity. In addition,
increasing the concentration of zymosan beyond 1 mg/ml, did
not appreciably reduce the hemolytic titre of unchelated
serum of this animal. Chelated serum of this individual did
not respond to increasing concentrations of zymosan.
The above functional studies demonstrate that an
alternative pathway of complement activation operates in
some form in the nurse shark. Its existence is indicated by
the following observations:
1. Nurse shark serum retains hemolytic activity in the
presence of EGTA, a selective chelator of calcium ions.
2. This calcium-independent alternative activity is enhanced
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by the addition of magnesium ions to EGTA and EDTA
chelated serum and.
3. Zymosan, an activator of mammalian alternative pathway
can deplete nurse shark serum of hemolytic activity in
the presence of EGTA.
In addition to providing evidence for the existence of
an alternative pathway of complement activation in the nurse
shark these studies have helped to establish a protocol by
which alternative pathway hemolytic activity can be assayed
for in nurse shark serum namely, by chelation of shark serum
with 20 mM EGTA for 30 minutes prior to assay employing 20
mM EGTA-10 mM Mg++-GVB as the assay buffer. Once the
parameters for assaying specifically for alternative pathway
activity had been established, it was then possible to
compare total hemolytic activity with alternative pathway
activity of several individual sharks against mammalian
erythrocyte targets. Tables 22-27 present total and
alternative pathway hemolytic titres of sera from several
animals using the six different types of mammalian
erythrocyte targets. Graphic representation of these data
is presented in figures 7 and 8.
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Immunoblots
Nurse shark serum was examined by immunoblotting
procedures in an attempt to provide evidence of proteins
antigenically similar to human complement proteins by
employing antisera to human complement components. Nurse
shark serum was probed with primary antibodies to human
complement components C3, C4, C5, factor B and factor H, and
the related thiolester-containing protein alpha 2
macroglobulin. It was hoped that nurse shark complement
components contain antigenically crossreactive epitopes
similar to their human counterparts which would be
recognized by antibody raised to the human proteins.
Dot blots were initially attempted using the Schleicher
and Schuell Minifold apparatus. Results of the initial dot
blot appear in figure 8. Human serum, used as a positive
control in this assay, reacted strongly with all primary
antisera tested. Contrary to expectation, a reaction was
also seen with normal rabbit serum, nurse shark serum and
when the secondary antisera alone was applied. The reaction
of human serum with normal rabbit serum and the secondary
antisera alone indicated nonspecific binding of the antisera
to these samples. Likewise, anti-CS antisera as a primary
antiserum gave a strong reaction with all samples, including
lysozyme, used as a negative control in this assay. The
nonspecific reaction of anti-human CS antisera (rabbit anti-
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human C5, Janssen Biochimica) invalidated results.
Additionally, coloring of membrane areas outside of wells
indicated leakage of samples from several wells. Although
blots of shark serum did react with anti-C3, C4 and factor B
and H antisera results were inconclusive as a reaction was
noted with non-immune rabbit serum used in place of the
primary antisera.
A second blot (figure 9) was prepared using a fresh
sample of human serum and varying the concentration of
samples and using a different source of primary antisera.
Results of this blot, shown in figure 9, show an improvement
in the specificity of the reaction with human serum and
primary antisera preparations. Shark serum, however,
demonstrated reactions with all antisera tested. The
intensity of reactions were no greater than the reaction
with non-immune rabbit serum. The anti-human alpha 2
macroglobulin antiserum showed uniform strong reaction with
all samples and therefore was rejected. Faint reactions
were seen with lysozyme.
A third blot (figure 10) was prepared using two
separate preparations of lysozyme (A and B), nurse shark
serum and human serum as test samples and primary antisera
similar to those used in the previous blot (figure 9). The
secondary antisera dilution was increased to 1:3000 from
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1:1000 used in the previous two blots in an attempt to
reduce the nonspecific reactions that occurred previously.
Unfortunately reducing the concentration of secondary
antisera produced reactions with several samples that were
too weak to be reliably interpreted.
To avoid sample leakage problems that occasionally
occurred with the Schleicher and Schuell Miniblot apparatus,
the BioRad dot blot apparatus was used to perform a fourth
blot. For the development of the fourth blot (figure 11)
the secondary antisera was diluted 1:1000. The human serum
sample gave the anticipated strong specific reactions with
all the primary antisera tested. Guinea pig serum as
antigen produced weaker but acceptable reactions with the
primary antisera used. However, lysozyme reacted
nonspecifically with anti-C3 and anti-C4 primary antisera.
The reactions produced between nurse shark serum samples and
anti-C3, C4, factor B and factor H were similar in intensity
to those obtained with non-immune rabbit serum or rabbit
gamma globulin fraction when used in place of the primary
antisera. This nonspecific reaction with rabbit serum
indicates that results with nurse shark serum are
inconclusive.
Western blots, whereby serum proteins are
electrophoretically separated before reaction with specific
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antisera, were performed in an attempt to eliminate the
apparent nonspecific reactions which had occurred in the dot
blots. Initially, both human and shark serum samples were
probed with several primary antisera preparations using the
BioRad Multiscreen apparatus as described in Materials and
Methods. In the case of human serum, blots (figure 12)
showed distinct reactive bands at position corresponding to
the approximate molecular weight of the human complement
component against which the specific antiserum in the lane
had been prepared. No analogous reactive bands appeared on
the membrane which contained transferred shark serum
proteins. As factor B is a complement component unique to
the alternative pathway, a Western blot was prepared and
screened using only anti-human factor B antisera as the
primary antibody. As only a single antiserum was being
used, it was not necessary to use the multiscreen apparatus.
Two gels, containing identical samples, were run
simultaneously. Lane 1 was loaded with a prestained low
molecular weight protein standard, lanes 2 and 3 were loaded
with 1:2 and 1:5 dilutions of shark serum respectively.
Lane 4 was loaded with a 1:5 dilution of human serum. One
gel was stained with Coomassie blue to illustrate protein
separation, (figure 13), while the other was used to
transfer proteins to a nitrocellulose membrane for
immunoblotting. Results of this immunoblot are shown in
figure 14. strong reaction with antihuman factor B antisera
55
is seen in lane 1 of the Western blot, which contained human
serum, however, neither dilution of nurse shark serum, lanes
2 and 3, showed a reaction with antiserum to human factor B.
The antiserum also showed a weak reaction with a low
molecular weight substance present in the human serum sample
which may be a breakdown fragment of factor B.
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TABLE 1
Agglutination of mammalian target erythrocytes
by nurse shark serum.
Tar et ervthrocytes
Shark Serum Rabbit Horse Bovine Shee
010992 238* 2048 64 2
010992 186 2048 32 2
010992 242 2048 2048 2
010992 241 2048 1048 2
010992 248** 2048 512 2
010992 244 2048 512 2
010992 88 2048 512 0
010992 463 2048 512 2
040692 248** 256
040692 463 16
040692 452 64
040692 489 128
040692 238* 64
040692 477 256
Table 1: Reciprocal of highest dilution of shark serum
showing agglutination of target cells. All target cells
used were unsensitized erythrocytes and standardized to 1
108 cells/ml.
* and ** are the same animals bled at different times.
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TABLE 2
Effect of time of preincubation of nurse shark serum in the
presence of varying amounts of EDTA on the hemolytic
activity of the serum
I. Horse erythrocyte targets
Concentration of EDTA (mM)
Time(min) 5mM 7.5mM 10mM 12.5mM 15m D cnt.
0 <2 <2 <2 nd nd >64
15 0 0 0 0 0 >64
30 0 0 0 0 0 >64
45 0 0 0 0 0 32
II. Sensitized Sheep erythrocvte targets
Concentration of EDTA (mM)
Time(min) 5mM 75 10mM 12.5mM 15mM G cnt
0 2 2 2 2 2 >64
15 <2 <2 <2 <2 <2 >64
30 0 0 0 0 0 >64
45 0 0 0 0 0 >64
Table 2: Values represent the reciprocal of the highest
serum dilution showing 50% lysis of target cells. A value
of <2 represents the presence of hemolysis at a dilution of
1:2 that is less than 50%. A value of 0 represents no
hemolysis at any dilution. Serum used in these experiments
was NSS 092591-2.
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TABLE 3
Effect of 15 and 30 minute preincubation periods for nurse
shark serum in the presence of various amounts of
EDTA on the hemolytic activity of the serum
against rabbit erythrocytes
Concentration of EDTA
Timelmin) 5mM 7.5M 10mM 12.5mM 15mM DGVB cont.
15 <2 <2 <2 <2 0 16
30 <2 <2 0 0 0 16
TABLE 3: Values represent the reciprocal of the highest
serum dilution showing 50% lysis of target cells. A value
of <2 represents hemolysis at a dilution of 1:2 that was
less than 50%. Nurse shark serum used in these experiments
was NSS 092591-3.
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TABLE 4
Effect of a 30 minute preincubation of nurse shark serum
in the presence of various concentrations of EDTA on
hemolytic activity of the serum against bovine
erythrocyte targets
Concentration of EDTA (mM)
Target 5mM 7.5mM 10mM 12.5mM 15mM DGVB cont.
sens. 0 0 0 0 0 >64
unsens. 0 0 0 0 0 16
Table 4: Target cells used were both sensitized (sens.) and
unsensitized (unsens.) bovine erythrocytes. Values indicate
the reciprocal of the last serum dilution showing 50%
hemolysis of target cells. Nurse shark serum used in these
experiments was NSS 092591-1.
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TABLE 5
The effect of preincubation time of nurse shark serum in the
presence of various concentrations of EGTA on the hemolytic
activity of the serum against mammalian target erythrocytes
I.Sensitized Bovine
EGTA conc._(mM) 15 min. 30 mi
0 (DGVB cont.) >64 >64
5 2 4
7.5 2 4
10 2 2
12.5 nd 2
15 nd 2
II.Unsensitized Bovine
EGTA conc. (mM) 15 min. 30 min.
0 (DGVB cont.) 8 16
5 4 4
7.5 8 2
10 4 2
12.5 nd 2
15 nd 2
III.Rabbit
EGTA conc._ mM) 15 min. 30 mim.
0 (DGVB cont.) 8 32
5 8 4
7.5 4 4
10 4 4
12.5 nd 4
15 nd 4
IV, Horse
EGTA conc. (mM) 15 mim. 30 min.
0 (DGVB cont.) 16 16
5 2 2
7.5 4 2
10 4 2
12.5 nd nd
15 nd nd
Table 5: Values represent reciprocal of the highest dilution
showing 50 % lysis of target cells. Nurse shark serum used
in these assays was NSS 092591-1. nd= not done.
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TABLE 6
Effect of EGTA concentration on the hemolytic activity of
nurse shark serum preincubated for 30 minutes in the
presence of EGTA
Target Erythrocytes
mMEGTA Sheep(S) Sheep(U) Bovine(S) Bovine(Ul Rabbit Horse
O(DGVB) >64 >64 64 16 32 16
5 4 nd 4 2 4 2
7.5 2 nd 2 2 4 2
10 2 nd 2 2 4 2
12.5 2 nd 2 2 4 2
15 2 2 2 2 4 2
17.5 2 2 2 2 4 2
20 2 2 2 2 4 2
22.5 2 2 2 2 4 2
25 2 2 2 2 4 2
30 2 2 2 2 4 2
35 2 2 2 2 4 2
40 2 2 2 2 4 2
45 2 2 2 2 4 2
50 2 2 2 2 4 2
Table 6:Values represent reciprocal of the highest serum
dilution showing 50% lysis of target cells. Sensitized
cells are indicated by (S) and unsensitized cells are
indicated by (U). Rabbit and horse erythrocytes were
unsensitized. nd= not done.
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TABLE 6a
Effect of 10mM EDTA on the hemolytic activity of nurse shark
serum against mammalian erythrocyte targets
Nurse shark serum 010992
tagis
Target cell 238 186 242 241 248 244 88 243 ean
Sheep(U) 0 0 0 0 2 4 2 2 1
Sheep(S) 0 0 0 0 0 2 0 0 0
Rabbit 0 0 0 0 0 0 0 0 0
Horse 0 0 0 0 0 0 0 0 0
Bovine (U) 0 0 0 0 0 0 0 0 0
Nurse shark serum 031892
tagjs
Target cell 230 241 465 455 477 489 Mean
Bovine(S) 0 0 0 0 0 0 0
Table 6a: A value of zero indicates no hemolysis at any
serum dilution. All sera were preincubated with 10 mM EDTA
for 30 minutes.
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TABLE 7
Effect of EGTA concentration on the hemolytic activity of
nurse shark serum against mammalian erythrocyte targets
I. Sensitized Seperythrocytes
Nurse shark serum 010992
tag#
mM EGTA 238 186 242 241 248 244 88 243 Mean SD
0(DGVB) 32 128 128 256 256 512 128 512 244 181
5 8 16 4 16 16 >32 16 32 18 10
10 8 8 4 8 16 32 16 16 14 9
15 4 8 4 8 8 32 16 16 12 9
20 4 8 4 8 8 32 8 16 11 9
25 4 4 2 16 8 16 16 16 10 6
II.Unsensitized sheep erythrocytes
Nurse shark serum 010992
tag#
mM EGTA 238 186 242 241 248 244 8 243 Mean SD
0 (DGVB) 32 32 32 128 128 1024 512 512 300 356
5 8 16 4 8 16 >32 16 >32 17 11
10 4 8 2 4 16 >32 16 32 14 12
15 4 8 2 4 16 32 8 16 11 10
20 4 4 2 4 8 32 8 16 10 10
25 2 4 2 2 8 16 8 16 7 6
III. Rabbit erythrocvtes
Nurse shark serum 010992 tag#
mMEGTA 238 186 242 241 248 244 88 243 Mean SD
0(DGVB) 64 32 32 32 64 128 128 128 72 45
5 16 16 16 16 32 >32 32 32 24 9
10 16 16 16 16 16 32 16 16 18 6
15 8 8 8 8 8 16 16 16 11 4
20 8 8 8 8 16 16 8 16 11 4
25 8 8 8 8 8 16 8 16 10 4
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TABLE 7 (cont)
IV. Horse erythrocytes
Nurse shark serum 010992 tac#
mM EGTA 238 186 242 241 248 244 88 243 Mean SD
0(DGVB) 16 64 32 32 32 256 64 32 66 79
5 4 4 4 4 4 4 8 8 5 2
10 2 4 4 2 4 4 4 8 4 2
15 2 2 4 2 2 4 4 4 3 1
20 0 2 2 2 2 2 4 4 2 1
25 0 2 2 0 2 2 2 4 2 1
V. Unsensitized bovine ervthrocytes
Nurse shark serum 010992 tag#
mM EGTA 238 186 242 241 248 244 88 243 Mean SD
0(DGVB) 16 16 32 32 32 128 32 64 44 37
5 2 2 4 4 4 8 4 4 4 2
10 2 2 4 2 2 4 4 2 3 1
15 2 0 2 2 2 4 2 2 2 1
20 0 0 2 2 2 2 2 2 2 1
25 0 0 2 2 2 2 2 2 2 1
VI. Sensitized bovine erythrocvtes
Nurse shark serum 022792 tag#j
mMEGTA 230 241 465 455 477 489 Mean SD
0 (DGVB) 32 64 16 32 32 32 35 16
5 8 8 4 2 8 4 6 3
10 8 4 2 2 8 2 4 3
15 8 4 2 2 4 4 4 2
20 4 4 2 0 4 2 3 2
25 4 4 2 0 4 2 3 2
Table 7: Values represent reciprocal of the highest serum
dilution showing 50% lysis of target cells. All serum was
preincubated for 30 minutes with the chelator.
SD=standard deviation of the mean.
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TABLE 8
Effect of EGTA on the hemolytic activity of nurse shark
serum against mammalian erythrocytes expressed as
percent of the control value
I. Sensitized sheep erythrocytes
Nurse shark serum 010992 tag#
mM EGTA 238 186 242 241 248 244 243 88 Mean SD
0(DGVB) 100 100 100 100 100 100 100 100 100 74
5 25 12.5 3.13 6.25 6.25 6.25 12.5 6.25 9.77 6.97
10 25 6.25 3.13 3.13 6.25 6.25 12.5 3.13 8.21 7.46
15 12.5 6.25 3.13 3.13 3.13 6.25 12.5 3.13 6.25 4.09
20 12.5 6.25 3.13 3.13 3.13 6.25 6.25 3.13 5.47 3.23
25 12.5 3.13 1.56 6.25 3.13 3.13 12.5 3.13 5.67 4.41
II. Unsensitized sheep erythrocytes
Nurse shark serum 010992 tag#
mMEGTA 238 186 242 241 248 244 88 243 Mean SD
0(DGVB) 100 100 100 100 100 100 100 100 100 117
5 25 50 12.5 6.25 12.5 3.13 3.13 6.25 14.9 15.9
10 12.5 25 6.25 3.13 12.5 3.13 3.13 6.25 9.0 7.55
15 12.5 25 6.25 3.13 12.5 3.13 1.56 3.13 8.4 7.96
20 12.5 12.5 6.25 3.13 6.25 3.13 1.56 3.13 6.06 4.29
25 6.25 12.5 6.25 1.56 6.25 1.56 1.56 3.13 4.88 3.78
III. Rabbit erythroc tes
Nurse shark serum 010992 tao#
mM EGTA 238 186 242 241 248 244 88 243 Mean SD
0 (DGVB) 100 100 100 100 100 100 100 100 100 59
5 25 50 50 50 50 25 25 25 37.5 13.4
10 25 50 50 50 25 25 25 12.5 34.9 12.9
15 12.5 25 25 25 12.5 12.5 12.5 12.5 17.2 6.5
20 12.5 25 25 25 25 12.5 6.25 12.5 18.0 7.8
25 12.5 25 25 25 12.5 12.5 6.25 12.5 16.4 7.4
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TABLE 8 (cant)
IV. Horse
Nurse shark serum 010992 tag
mMEGTA 238 186 242 241 248 244 88 243 Mean SD
0(DGVB) 100 100 100 100 100 100 100 100 100 119
5 25 6.25 12.5 12.5 12.5 1.56 12.5 25 13.5 8.1
10 12.5 6.25 12.5 6.25 12.5 1.56 6.25 25 10.2 7.1
15 12.5 3.13 12.5 6.25 6.25 1.56 6.25 12.5 7.6 4.4
20 0 3.13 6.25 6.25 6.25 0.78 6.25 12.5 5.2 3.9
25 0 3.13 3.25 0 6.25 0.78 3.13 12.5 4.0 4.3
V. Unsensitized bovine
Nurse shark serum 010992 tac#
mM EGTA 238 186 242 241 248 244 88 243 Mean SD
0 (DGVB) 100 100 100 100 100 100 100 100 100 84
5 12.5 12.5 12.5 12.5 12.5 6.25 12.5 6.25 10.9 2.9
10 12.5 12.5 12.5 6.25 6.25 3.13 12.5 3.13 8.6 4.3
15 12.5 0 6.25 6.25 6.25 3.13 6.25 3.13 5.5 3.6
20 0 0 6.25 6.25 6.25 1.56 6.25 3.13 3.7 2.9
25 0 0 6.25 6.25 6.25 1.56 6.25 3.13 3.7 2.9
VI. Sensitized bovine erythrocytes
Nurse shark serum 022792 taci#
mMEGTA 230 241 465 455 477 489 Mean SD
0 (DGVB) 100 100 100 100 100 100 100 45
5 25 12.5 25 6.25 25 6.25 16.7 9.4
10 25 6.25 12.5 6.25 25 3.13 13.0 9.8
15 25 6.25 12.5 6.25 12.5 3.13 11.0 7.8
20 12.5 6.25 12.5 0 12.5 3.13 7.8 5.5
25 12.5 6.25 12.5 0 12.5 3.13 7.8 5.5
Table 8: Values represent hemolytic titre expressed as
percent of control titre determined by hemolytic assay of
nurse shark serum in DGVB++. Standard deviation (SD) of
controls were determined by conversion of absolute titre to
100 and determining a factor from the ratio of the absolute
titre to 100. This factor was then used to multiply the
standard deviation of the absolute titre to yield the
standard deviation given in the table. SD= standard
deviation of the mean.
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TABLE 9
Statistical analysis of the effect of EGTA on the hemolytic
activity of nurse shark serum expressed as percent
of control
Target ervthrocytes
I. Sensitized shee
mM EGTA Mean SD t value
5 9.77 6.97 36.5
10 8.21 7.46 33.8
15 6.25 4.09 66.9
20 5.47 3.23 81.5
25 5.67 4.41 60.1
II. Unsensitized sheep
mMEGTA Mean SD t value
5 14.85 15.91 15.1
10 8.99 7.55 34.1
15 8.40 7.96 32.5
20 6.06 4.29 61.9
25 4.88 3.78 71.2
III. Rabbit
mEGTA Mean SD t value
5 37.50 13.36 13.2
10 34.38 12.94 12.8
15 17.19 6.47 36.2
20 17.97 7.79 29.8
25 16.41 7.42 31.9
IV. Horse erythrocvtes
mM EGTA Mean SD t value
5 13.48 8.14 30.1
10 10.35 7.13 35.5
15 7.62 4.37 59.7
20 5.18 3.94 68.1
25 4.01 4.25 65.7
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TABLE 9 _(ont.)
V. Unsensitized bovine erythrocytes
mM EGTA Mean SD t value
5 10.94 2.89 93.5
10 8.60 4.34 59.6
15 5.47 3.64 73.5
20 3.71 2.89 94.4
25 3.71 2.89 94.4
VI. Sensitized bovine erythrocytes
mM EGTA Mean SD t value
5 16.67 9.41 22.2
10 13.02 9.77 22.3
15 10.97 7.81 28.4
20 7.80 5.50 41.9
25 7.80 5.50 41.9
Table 9: Paired t test was performed to compare mean
hemolytic titres of treated serum with those of untreated
serum for each target cell and concentration of EGTA tested.
For sensitized sheep, unsensitized sheep, rabbit, horse and
unsensitized bovine erythrocyte targets n=8. For sensitized
bovine target cells n=6. All t values were greater than the
critical value (p<0.005), demonstrating that the drop in
titre as a result of incubation in the presence of EGTA was
statistically significant for all levels of EGTA tested and
against all target cells used. SD= standard deviation of
the mean.
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TABLE 10
The effect of added magnesium on the hemolytic activity of
nurse shark serum chelated with 20 mM EGTA
I.Rabbit erythrocvtes
Mg++ added
NSS022792tacg DGVB+ 0mM imv 5mM 100mM 15mM 20mM
453 128 16 64 64 64 64 128
466 256 16 32 32 64 64 64
230 128 16 32 64 64 64 64
241 256 16 32 32 64 64 64
465 32 8 32 32 32 32 32
455 32 8 16 16 32 32 32
477 128 16 32 64 64 64 64
489 64 8 32 32 32 32 32
Mean 128 13 34 42 52 52 60
SD 89 4 13 19 17 17 31
II.Sensitized sheer erythrocvtes
mM Mg++ added
NSSO43092tag# DGVB++ 0mM 1mM 5mM 10mM 15mM 20mM
186 1024 32 128 128 256 128 256
242 64 2 16 32 32 64 64
248 1024 32 128 128 128 128 128
489 1024 >32 256 256 512 512 256
Mean 784 25 132 134 232 208 176
SD 480 15 98 88 208 205 96
III. Unsensitized sheep erythrocvtes
mM MQ++ added
NSSO31992tag# DGVB++ 0m 1mM _5m 10M 15mM 20mM
489 128 8 32 32 64 64 64
452 256 8 8 32 64 64 64
477 32 4 16 16 16 32 32
248 128 4 16 32 32 32 32
242 32 4 16 16 16 16 16
238 64 0 16 16 32 32 32
Mean 107 5 17 24 37 40 40
SD 85 3 7.9 8.8 22 20 20
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TABLE 10 (con't)
IV. Horse ervthrocvtes
mM MQ++ added
NSS022792taq DGVB++ OmM 1 5mM 1mM _1_5m 20mM
465 16 4 8 16 16 16 16
241 64 4 32 64 64 128 128
455 64 8 16 32 64 64 64
453 128 16 32 64 512 256 256
466 32 8 32 64 128 128 128
230 64 8 32 64 128 128 128
477 32 4 8 16 32 32 32
489 64 4 8 16 32 32 32
Mean 58 7 21 46 122 98 98
SD 34 4 12 23 163 80 80
V. Sensitized bovine erythrocvtes
mM M++ added
NSS043092tag# DGVB++ OmM 1mM 5mM 10mM 15mM 20mM
456 512 16 64 64 128 64 64
242 32 2 16 32 64 32 16
248 256 16 64 64 64 32 64
186 512 32 128 64 64 64 64
489 1024 16 64 32 64 64 64
238 256 32 32 32 128 64 64
Mean 432 19 61 48 85 53 56
SD 342 11 38 18 33 17 20
VI. Unsensitized bovine erythrocytes
mM Mc++ added
NSSO22792ta# DGVB++ OmM 1mM 5mM 10mM 15mM 20mM
453 256 8 32 64 64 64 64
477 64 4 8 16 16 16 32
455 64 2 4 8 16 16 16
466 128 16 64 64 64 64 64
230 128 16 32 64 64 64 64
241 256 4 16 32 32 32 32
465 16 2 4 8 8 16 16
489 256 8 16 16 16 16 16
Mean 201 8 22 32 35 36 38
SD 94 6 20 27 25 24 23
Table 10: Values indicate reciprocal of the highest serum
dilution showing 50% lysis of target cells. All serum
samples were chelated with 20 mM EGTA before addition of
magnesium ions. SD= standard deviation of the mean.
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TABLE 11
The effect of added magnesium ions on the hemolytic activity
of nurse shark serum chelated with 20mM EGTA
against mammalian erythrocytes expressed as
percent of control titre
I. Rabbit erythrocytes
mM Mg++ added
NSS022792tag# DGVB++ 0mM 1mM 5mM 10mM 15mM 20mM
453 100 12.5 50 50 50 50 100
466 100 6.25 12.5 12.5 25 25 25
230 100 12.5 25 50 50 50 50
241 100 6.25 12.5 12.5 25 25 25
465 100 25 100 100 100 100 100
455 100 25 50 50 100 100 100
477 100 12.5 25 50 50 50 50
489 100 12.5 50 50 50 50 50
Mean 100 14 41 47 56 56 63
SD 69 7 29 27 29 29 33
II. Sensitized sheep erythrocvtes
mM MQ++ added
NSSO43092tac# DGVB++ 0mM 1mM 5mM 10mM 15mM 20mM
186 100 3.13 12.5 12.5 25 12.5 25
242 100 3.13 25 50 50 100 100
248 100 3.13 12.5 12.5 12.5 12.5 12.5
489 100 3.13 25 25 25 50 25
Mean 100 3.13 19 25 34 44 41
SD 61 0 7 18 19 42 40
III, Unsensitized sheep erythrocytes
mM Mg++ added
NSS031992tag# DGVB++ 0mM 1mM 5mM 10mM 15mM 20mM
489 100 6.25 25 25 50 50 50
452 100 3.13 3.13 12.5 25 25 50
477 100 12.5 50 50 50 100 100
248 100 3.13 12.5 25 25 25 25
242 100 12.5 50 50 50 50 50
238 100 0 25 25 50 50 50
Mean 100 6 28 31 42 50 50
SD 79 5 19 15 13 27 27
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TABLE 11 (con't)
_IV. Horse erytrocyts
mMM++ added
NSS022792tag# DGVB++ 0_m 1mM 5mM 10mM 15mM 20mM
465 100 25 50 100 100 100 100
241 100 6.25 50 100 100 200 200
455 100 12.5 25 50 100 100 100
453 100 12.5 25 50 400 200 200
466 100 25 100 200 800 200 200
230 100 12.5 50 100 200 200 200
477 100 12.5 25 50 100 100 100
489 100 6.25 12.5 25 50 50 50
Mean 100 14 42 59 231 219 219
SD 58 7 28 58 255 242 242
V. Sensitized bovine erythrocvtes
mM Mc++ added
NSS043092tag# DGVB++ 0mM 1mM 5mM 10mM 15mM 20mM
456 100 3.13 12.5 12.5 25 12.5 12.5
242 100 6.25 50 100 200 100 50
248 100 6.25 25 25 25 12.5 25
186 100 6.25 25 25 12.5 12.5 12.5
489 100 1.56 6.25 3.13 6.25 6.25 6.25
238 100 12.5 12.5 12.5 50 25 25
Mean 100 6 22 30 53 28 22
SD 78.7 4 16 36 74 36 16
VI. Unsensitized bovine erythrocytes
mM Mg++ added
NSS022792t ag DGVB++ 0mM +mM 5mM 10mM 15mM 20mM
453 100 3.13 12.5 25 25 25 25
477 100 6.25 12.5 25 25 25 50
455 100 3.13 6.25 12.5 25 25 25
466 100 12.5 50 50 50 50 50
230 100 12.5 25 50 50 50 50
241 100 1.56 6.25 12.5 12.5 12.5 12.5
465 100 12.5 25 50 50 100 100
489 100 3.13 6.25 6.25 6.25 6.25 6.25
Mean 100 6.0 18 29 30 38 40
SD 67 4.6 15.1 18.6 17.5 30 30
Table 11: Values represent the hemolytic activity of the
serum expressed as a percent of the DGVB++ control titre.
SD=standard deviation of the mean.
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TABLE 11a
Statistical analysis of the effect of added magnesium on the
hemolytic titre or nurse shark serum chelated with
20 mM EGTA expressed as a percent of
control value
Tar et ervthrocyste
I. Rabbit erytrocvts
mM Mg++ added Mean SD t value
1 41 28.9 3.19 p<0.01
5 47 27.4 4.21 p<0.005
10 56 29.0 5.40 p<0.005
15 56 29.0 5.40 p<0.005
20 63 33.0 5.00 p<0.005
II. Sensitized sheep ervthrocytes
mM Mg++ added Mean SD t value
1 18.8 7.2 4.339 p<0.025
5 25 17.7 2.500 p<0.05
10 34.4 18.8 3.205 p<0.025
15 43.8 41.5 1.959 p<0.10
20 40.6 40.0 1.875 p<0.10
III. Unsensitized sheep erythrocytes
mM Mg++ added Mean SD t value
1 27.6 19.2 3.452 p<0.01
5 31.3 15.3 5.568 p<0.005
10 41.6 12.9 7.560 p<0.005
15 50.0 27.4 4.419 p<0.005
20 50.0 27.4 3.906 p<0.01
IVl. Horse erthrocytes
mM Mg++ added Mean SD t value
1 42.2 27.5 3.906 p<0.01
5 59.3 57.5 3.912 p<0.01
10 231 255 2.651 p<0.025
15 219 242 8.929 p<0.005
20 219 242 8.929 p<0.005
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TABLE _la co't).
V. Sensitized bovine erythrocytes
mM Mg++ added Mean SD t value
1 21.9 15.7 2.500 p<0.05
5 29.7 35.5 1.646 p<0.10
10 53.0 73.5 1.586 p<0.10
15 28.1 35.7 1.535 p<0.10
20 21.9 15.7 2.680 p<0.025
VI. Unsensitized bovine erythrocytes
mM Mg++ added Mean SD t value
1 18 15.1 5.889 p<0.005
5 29 18.6 4.420 p<0.005
10 30 17.5 5.075 p<0.005
15 38 30 3.213 p<0.01
20 40 30 3.549 p<0.005
Table la: Paired t test was performed to compare hemolytic
titres of chelated serum to which no magnesium was added to
with those of chelated serum to which magnesium had been
added for each target cell and level of magnesium added.
For rabbit, horse and unsensitized bovine erythrocytes n=8;
for unsensitized sheep erythrocyte targets n=6; for
sensitized sheep erythrocyte targets n=4. All t values
greater than the critical value at p<0.05 or less were
considered statistically significant.
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TABLE 12
The effect of 10mM added magnesium on the hemolytic activity
of nurse shark serum chelated with 10mM EDTA
against sheep and bovine erythrocytes
I. nsensitized sheen ervtrocyts
NSS031992ta# DGVB++ 10mM EDTA 1 + 1
489 128 0 16
452 256 0 16
477 32 0 8
248 128 0 16
242 32 0 8
238 64 0 4
Mean 107 0 11
SD 85 0 5
II. Sensitized sheep ervthrocytes
NSSO43092tag# DGVB++ 10mMEDTA 10mM EDTA + 10mM Mg
186 1024 2 256
242 64 0 8
248 1024 2 64
489 1024 4 128
Mean 784 2 114
SD 480 2 107
III. Sensitized bovine ervthrocytes
NSS043092tag# DGVB+ 10mM EDTA 10mM EDTA + 10mM Mg
456 512 2 64
242 32 0 2
248 256 0 32
186 512 2 128
238 256 0 64
Mean 314 1 58
SD 203 1 47
Table 12: Values represent the reciprocal of the highest
serum dilution showing 50% lysis of target cells.
SD= standard deviation of the mean.
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TABLE 13
The effect of incubation temperature on the hemolytic
activity of nurse shark serum against
mammalian target cells
I Rabbit ervthrocvtes
NSS101891-1 NSSl0l89l-1
Temperature Total ACP Total ACP
6C 16 8 16 8
23'C 64 8 32 16
30CC 32 4 32 4
370C 32 16 32 8
II. Horse erythrocytes
NSS101891-3 NSS101891-6
Tem erature Total ACP Total ACP
60C 8 16 8 16
230C 32 128 4 128
300C 32 64 32 64
370 C 16 32 16 16
III. Sensitized sheep erythrocytes
NSSl891-3 NSS101891-1
Temperature Total ACP Total ACP
6 C 64 8 64 16
23 0 C 128 64 256 64
300C 256 16 256 8
37OC 128 32 64 16
IV. Unsensitized sheep erythrocytes
NSS10189l-3 NSS11891-6
Temperature Total ACP Total ACP
60C 64 168
23CC 64 16 32 16
300C 128 16 32 4
370C nd 32 32 16
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TABLE 13 (con't)
V. Sensitized bvine erytrocvtes
NSS101891-1 NSS101891-6
Temperature Total ACP Total ACP
6C 64 8 16 8
230C 64 32 64 64
300C 16 8 16 8
37 0 C 16 16 32 16
VI. Unsensitized bovine erythrocytes
NSS101891-1 NSS101891-6
Ternerature Total ACP Total ACP
6 C 8 16 16 8
23 0C 32 32 32 32
3O0C 16 8 16 8
37 0C 16 16 32 16
Table 13: Values represent the reciprocal of the highest
serum dilution showing 50% lysis of the target cells. nd=
not done. Total complement activity was measured in DGVB++,
while alternative pathway activity was assayed in 20 mM
EGTA-10 mM Mg++-GVB.
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TABLE 13a
The effect of incubation temperature on the alternative
pathway hemolytic activity of nurse shark serum
I. Rabbit erythrocyte targets
NSS tag # 23 C 300 C
463 64 64
456 32 64
238 32 64
242 16 16
II. Horse erythrocyte targets
NSS tac# 23'C 300_C
463 32 32
456 32 32
238 16 16
242 4 4
Table 13 a: Values represent the reciprocal of the highest
serum dilution showing 50% lysis of target cells. All serum
was chelated with 20mM EGTA prior to assay. Assay buffer
was 20 mM EGTA-10 iM Ng++-GVB.
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TABLE 14
The effect of increased incubation times on the hemolytic
activity of nurse shark serum against
horse erythrocyte targets
NSS101891-3 NSS101891-6
231C 300 C 23C 300C
Time Total ACP Total ACP Total ACP Total ACP
1 HR 32 128 32 64 4 128 32 64
2 HR 32 64 32 64 32 64 32 64
4HR 16 32 64 64 16 32 32 32
Table 14: Values represent the reciprocal of the highest
serum dilution showing 50% lysis of target cells.
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TABLE 15
The effect of zymosan on the hemolytic activity of
nurse shark serum
I. Sensitized sheer targets
Incubation Concentration
time Omg/ml 1mg/ml 5mg/ml 10mg/ml
o time 128 nd nd nd
90 min 32 16 4 4
3hours 32 4 4 4
overnight 8 2 2 2
II. Rabbit cell targets
Incubation Concentration
time 0mg/ml 1mg/ml 5mg/ml 10mg/ml
O time 8 nd nd nd
90 min 8 4 2 2
3hours 8 4 0 0
overnight 0 0 0 0
Table 15: Values represent the reciprocal of the highest
serum dilution showing 50% lysis of target cells. Nurse
shark serum used for these assays was 111491 tag#186. Serum
assayed against sensitized sheep cells was nonchelated.
Serum assayed against rabbit cells was chelated with 20mM
EGTA prior to incubation in the presence of zymosan. nd=
not done.
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TABLE 16
The effect of LPS on the hemolytic activity of nurse
shark serum
I. Sensitized sheep cell targets
Incubation Concentration
time Omg/ml 1mg/mi 5mg/ml 10mg/ml
0 time 8 nd nd nd
90 min 4 4 4 4
4.5 hours nd 2 2 2
II. Rabbit cell targets
Incubation Concentration
time Omc/ml 1mg/ml 5mg/ml 10mg/ml
Otime 4 nd nd nd
90 min 4 4 2 2
3hours 4 4 2 <2
4.5 hours 4 4 2 <2
overnight 0 0 0 0
Table 16: Values indicate the reciprocal of the highest
dilution showing 50% lysis of target cells. Nurse shark
serum used in these assays was NSS 101891-3. nd=not done.
Serum used in assays against both target cells was
nonchelated.
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TABLE 17
The effect of cobra venom factor on the hemolytic activity
of nurse shark serum
I. Sensitized sheep cell targets
Incubation Concentration
time Omg/m 0 .O5mcr/ml 0 . 125mg/m 0 .50mg/ml
0 time 16 nd nd nd
90 min 16 16 16 16
4.5 hours 16 16 16 16
II. Rabbit cell targets
Incubation Concentration
time Omg/ml 0. 05mg /ml 0.125mg/mi 0.50mg/ml
0 time 16 nd nd nd
90 min 16 16 16 8
3 hours 16 16 16 16
4.5 hours 8 8 8 8
overnight 8 4 4 4
Table 17: Values represent the reciprocal of the highest
serum dilution showing 50% lysis of target cells. Nurse
shark serum used in these assays was NSS 101891-1. nd= not
done.
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TABLE 18
The effect of inulin on the hemolytic activity of nurse
shark serum on rabbit erythrocyte targets
Incubation Concentration
time Oma/ml 1mg/ml 5mg/ml 10mg/ml
0 time 4 nd nd nd
90 min 4 2 2 4
3hours 2 2 4 4
4. 5hours 2 2 2 2
overnight 0 0 0 0
Table 18: Values represent the reciprocal of the highest
serum dilution showing 50% lysis of target cells. nd= not
done. Nurse shark serum used in these assays was NSS
101891-3.
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TABLE 19
The effect of zymosan on the hemolytic activity of
unchelated nurse shark serum
(additional individuals)
I. Sensitized sheep cell targets
NSS 043092 Incubation Concentration
t# time _mgm 1ml 5m/ml 0mml
463 0 time 512 512 256 128
90 min 256 32 32 8
3 hours 256 16 8 4
4.5 hours 128 4 4 4
456 0 time 512 256 256 128
90 min 512 64 32 32
3 hours 128 16 16 16
4.5 hours 128 16 16 16
II, Rabbit cell targets
NSS 043092 Incubation Concentration
t# time Omg/ml m/ml mg/ml 10mg/ml
463 0 time 64 64 32 32
90 min 32 8 8 8
3 hours 16 8 4 4
4.5 hours 8 8 2 2
456 0 time 128 128 64 64
90 min 64 16 16 16
3 hours 32 16 16 16
4.5 hours 32 8 8 8
Table 19: Values represent the reciprocal of the last serum
dilution showing 50% lysis of target cells. All serum
samples used in these experiments were unchelated. Assay
buffer was DGVB++.
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TABLE 20
The effect of zymosan on the alternative pathway hemolytic
activity of chelated nurse shark serum against
rabbit erythrocyte targets
NSS 043092 Incubation Concentration
tag# time Om /ml 1mg/ml 5mg/ml 10mg/ml
463 0 time 32 32 32 32
90 min 32 16 8 2
3 hours 16 8 2 0
4. hours 8 0 0 0
456 0 time 8 16 16 8
90 min 16 4 4 4
3 hours 16 8 16 16
4.5 hours 16 8 16 16
Table 20: Values represent the reciprocal of the last serum
dilution showing 50% lysis of target cells. All serum used
was chelated with 20 mM EGTA prior to assay. Assay buffer
was 20 mM EGTA-10 mM Mg++-GVB.
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The effect of LPS on the hemolytic activity of nurse
shark serum NSS043092 tag#463
I. Sensitized sheep cell targets
Incubation Concentration
time Omaiimi 1lg//m 5mgmi 10mcimi
0 time 128 128 128 128
90 min 64 64 32 16
3 hours 32 32 16 8
4.5 hours 16 16 16 8
II. Rabbit cell targets
Incubation Concentration
time 0mg/ml 1mg/ml 5mg/ml 10mg/mi
0 time 32 32 32 32
90 min 8 8 16 8
3 hours 8 8 8 8
4.5 hours 4 2 8 4
Table 21 Values represent the reciprocal of the last serum
dilution showing 50% lysis of target cells. Serum used in
assays where sensitized sheep cells were targets was
unchelated and the assay buffer for these experiments was
DGVB++. Serum samples used in assays where rabbit cells
were targets was chelated with 20 mM EGTA prior to assay.
Assay buffer for these experiments was 20 mM EGTA-10 mM
Mg++-GVB.
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TABLE 22
Total and alternative pathway hemolytic titres of several
nurse shark sera against rabbit erythrocyte targets
Nurse shark Total activity Alternative pathway
serum titre titre
022792 tag 477 64 64
022792 tag 489 64 32
022792 tag 230 512 64
011992 tag 248 64 32
011992 tag 244 256 128
011992 tag 88 64 32
011992 tag 463 128 128
022792 tag 453 128 64
022792 tag 466 512 64
022792 tag 241 128 64
022792 tag 465 64 32
022792 tag 455 32 32
011992 tag 238 128 64
011992 tag 186 64 32
011992 tag 242 64 32
011992 tag 241 64 32
Mean=146 Mean=56
SD=152 SD=32
n=16
Table 22: Values represent the reciprocal of the highest
serum dilution showing 50% lysis of target cells. Means of
total and alternative pathway titres were compared by paired
t test. The two means were found to be statistically
significantly different at a confidence level of p<0.02.
SD= standard deviation of the mean.
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TABLE 23
Total and alternative pathway hemolytic titres of several
nurse shark sera against horse erythrocyte targets
Nurse shark Total activity Alternative pathway
serum titre titre
022792 tag 230 128 128
022792 tag 477 32 32
022792 tag 489 64 32
011992 tag 248 128 32
011992 tag 244 512 128
011992 tag 88 64 16
011992 tag 463 128 32
022792 tag 453 512 512
022792 tag 466 64 256
022792 tag 241 128 64
022792 tag 465 32 16
022792 tag 455 128 64
011992 tag 238 32 16
011992 tag 186 64 16
011992 tag 242 64 32
011992 tag 241 64 32
Mean=134 Mean=88
SD=152 SD=130
n=16
Table 23: Values represent the reciprocal of the highest
serum dilution showing 50% lysis of the target cells. Means
of total and alternative pathway hemolytic titres were
compared by the paired t test. The two means were found to
be not statistically significantly different. SD=standard
deviation of the mean.
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TABLE 24
Total and alternative pathway hemolytic titres of several
nurse shark sera against sensitized sheep
erythrocyte targets
Nurse shark Total activity Alternative pathway
serum titre titre
011992 tag 248 256 16
011992 tag 244 1024 32
011992 tag 88 512 16
011992 tag 463 512 32
043092 tag 248 1024 128
043092 tag 489 1024 512
043092 tag 456 1024 256
011992 tag 238 64 16
011992 tag 186 128 8
011992 tag 241 64 8
011992 tag 242 128 8
043092 tag 186 1024 256
043092 tag 242 64 64
043092 tag 238 1024 128
Mean=562 Nean=106
SD=439 SD=146
n=14
Table 24: Values represent the reciprocal of the highest
serum dilution showing 50% lysis of the target cells. The
means of total and alternative pathway hemolytic titres was
compared by the paired t test. The two means were found to
be statistically significantly different at a confidence
level of p<0.001. SD= standard deviation of the mean.
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TABLE 25
Total and alternative pathway hemolytic titres of several
nurse shark sera against unsensitized sheep
erythrocyte targets
Nurse shark Total activity Alternative pathway
serum titre titre
031992 tag 489 128 64
031992 tag 248 128 32
022792 tag 477 64 16
011992 tag 248 128 32
011992 tag 244 512 32
011992 tag 88 256 32
011992 tag 463 256 32
031992 tag 452 256 64
031992 tag 238 64 32
031992 tag 242 nd 16
011992 tag 238 32 16
011992 tag 186 64 16
011992 tag 242 32 16
011992 tag 241 128 16
Mean=158 Mean=30
SD=134 SD=16
n=13
Table 25: Values represent the reciprocal of the last serum
dilution showing 50% lysis of target cells. The mean of
total and alternative pathway hemolytic titres were compared
by paired "t" test. The two means were found to be
statistically significantly different at a confidence level
of p<0.003. SD= standard deviation of the mean.
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TABLE 26
Total and alternative pathway hemolytic titres of several
nurse shark sera against unsensitized bovine
erythrocyte targets
Nurse shark Total activity Alternative pathway
serum titre titre
022792 tag 230 128 64
022792 tag 477 128 16
022792 tag 489 256 16
011992 tag 248 16 8
011992 tag 244 64 32
011992 tag 88 32 8
011992 tag 463 64 8
022792 tag 453 256 64
022792 tag 466 256 64
022792 tag 241 128 32
022792 tag 465 64 8
022792 tag 455 64 16
011992 tag 238 16 8
011992 tag 186 16 4
011992 tag 241 16 16
011992 tag 242 16 16
Mean=95 Nean=24
SD=89 SD=21
n=16
Table 26:Values represent the reciprocal of the highest
serum dilution showing 50% lysis of target cells. The means
of total and alternative pathway hemolytic titres were
compared by paired t test. The two means were found to be
statistically significantly different at a confidence level
of p<0.0001. SD= standard deviation of the mean.
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TABLE 27
Total and alternative pathway hemolytic titres of several
nurse shark sera against sensitized bovine
erythrocyte targets
Nurse shark Total activity Alternative pathway
serum titre titre
043092 tag 456 512 128
043092 tag 248 512 64
043092 tag 489 1024 64
011992 tag 248 1024 8
011992 tag 244 1024 16
011992 tag 88 512 8
011992 tag 463 256 8
043092 tag 242 64 64
043092 tag 186 512 64
043092 tag 238 512 128
011992 tag 238 64 16
011992 tag 186 256 16
011992 tag 241 256 16
011992 tag 242 256 16
Mean=485 Mean=44
SD=333 SD=43
n=14
Table 27: Values represent reciprocal of highest serum
dilution showing 50% lysis of target cells. Means of total
and alternative pathway hemolytic titres were compared by
paired t test. The two means were found to be statistically
significantly different at a confidence level of p<0.005.
SD= standard deviation of the mean.
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Figure 1: The effect of EGTA on the hemolytic activity of
nurse shark serum. Shark serum was incubated for 30 minutes
in the presence of the stated millimolar amount of chelator
prior to assay for hemolytic activity. Hemolytic assays
were done in microtitre plates using EGTA-GVB-- as the assay
buffer. Each serum was assayed in buffer containing an
equivalent amount of EGTA to that in which it was incubated
prior to performing the assay. Each bar represents the
average hemolytic titre of eight individual animals
expressed as a percent of the control titre. The control
titre is represented by solid bar and is determined by assay
of the same serum in DGVB++, without prior incubation in the
presence of EGTA under similar conditions as the treatment
groups. for that particular treatment group. Error bars
represent the standard deviation of each group of data.
Standard deviation for the control titres was determined by
calculating a factor that converts the average of the
absolute titres to 100 and multiplying the standard
deviation of the absolute titres by this factor.
94
FIGURE 1
POPS-j
Hill
(( } 3 G' i gym.
t
i ,yy
k 
_
---- ----- -- --
L-J144
a I 
1
r
LIJ
w
-x p'
'mss
v i A
Lij
..__-rv., . _..,...,._ ... . _.__ _. _...._.
and I k
f 
3
LIJ
CTO
0
I
i
zf 
h
LIJ 
FRI
Lul.
r w 'tea
m 
_
,$ 
t 
qa it
y 
GLLIU
LULL.
LUL.
iLWI s g y
.
CSC 
_'F 
.o. r a":. mac, y ,a ¬"yii l 5.
95
Figure 2: The effect of added magnesium on the hemolytic
activity of nurse shark serum chelated with 20 mM EGTA.
Shark serum was incubated in the presence of 20 mM EGTA for
30 minutes prior to assay for hemolytic activity. Hemolytic
assays were done in microtitre plates using 20 mM EGTA-Mg++-
GVB as the assay buffer. Each bar represents the average
hemolytic titre expressed as a percent of the control,
represented by a solid bar, determined by assay of the same
serum in DGVB++ without prior incubation in the presence of
EGTA. Hemolytic titres against rabbit, unsensitized sheep
and bovine and horse erythrocytes, represent the average of
eight individual animals. Titres against sensitized sheep
and bovine erythrocytes represent the average of four
individuals and six individuals respectively. Each group of
sera was assayed with buffer containing the 0, 1, 5, 10, 15
or 20 mM magnesium as indicated. Error bars represent the
standard deviation of the means. Standard deviation for the
controls were determined by calculation of a factor that
converts the mean of the absolute titres to 100. The
standard deviation of the absolute titres is then multiplied
by this factor.
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Figure 3: Depletion of hemolytic activity of nurse shark
serum by incubation with zymosan. Nurse shark serum was
incubated in the presence of 0, 1, 5 or 10 mg/ml of zymosan
at 300C in a shaking water bath for 90 minutes and 3 hours.
Serum was then assayed for residual hemolytic activity in
DGVB++ using sensitized sheep erythrocytes as targets. Bars
represent the hemolytic titre of the serum expressed as a
percent of the titre of the serum incubated for the same
time period without zymosan. These data were obtained from
a single individual, 111391 tag#186.
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Figure 4:Depletion of hemolytic activity of chelated nurse
shark serum by incubation with zymosan. Nurse shark serum
chelated with 20 mM EGTA was incubated in the presence of 0,
1, 5, and 10 mg/ml of zymosan at 3O0C in a shaking water
bath for 90 minutes and 3 hours. Serum was then assayed for
residual hemolytic activity in 20 mM EGTA-lO mM Mg++-GVB
using rabbit erythrocyte targets. Bars represent the
hemolytic titre expressed as a percent of the control titre
which was serum incubated for the same time period without
zymosan. These data were obtained from a single individual
11491 tag#186.
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Figure 5: Depletion of hemolytic activity of nurse shark
serum by lipopolysaccharide (LPS). Nurse shark serum was
incubated in the presence of 0, 1, 5 and 10 mg/ml LPS at
30 0C in a shaking water bath for 90 minutes, 3 hours and 4,5
hours, Serum was then assayed for hemolytic activity in
DGVB++ using rabbit erythrocyte targets. Bars represent the
hemolytic titre expressed as a percent of the control titre,
which was serum incubated for the same time period without
LPS. These data were obtained from a single individual
111491 tag#186.
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Figure 6: Effect of zymosan on the hemolytic activity of
serum from nurse shark 043092 tag # 463. Nurse shark serum
was incubated in the presence of 0, 1, 5, and 10 mg/ml
zymosan at 300C in a shaking water bath for 90 minutes, 3
hours and 4.5 hours. Serum was then assayed for residual
hemolytic activity in DGVB++ using sensitized sheep
erythrocyte targets. Bars represent the hemolytic titre
expressed as a percent of the control titre, which was serum
incubated for the same time period without zymosan.
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Figure 7: Comparison of the total and alternative pathway
hemolytic titres of nurse shark serum. Bars represent the
average total and alternative hemolytic titres of several
individuals. The values of hemolytic titres against rabbit,
horse and unsensitized bovine cells are the mean of 16
samples. The values of titres against sensitized sheep and
bovine erythrocyte targets are the mean of 14 samples and
the values for unsensitized sheep targets is the mean of 13
samples. Error bars indicate the standard deviation of the
samples.
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Figure 8: Initial dot blot experiment. The vertical sample
columns are labelled with the test sample that was applied
to the membrane. Several dilutions of nurse shark serum,
(1:2-1:1000) three dilutions of human serum (1:100-1:1000)
and two dilutions of lysozyme were applied as test samples.
Primary antisera used on all samples are listed
horizontally. Rabbit anti human C3, C4, C5, factor B and
factor H antisera, diluted 1:30 in antibody buffer, were
used as primary antisera. Non-immune rabbit serum (NRS),
nurse shark serum (012391-1) from a different individual and
a sample of the secondary antibody preparation were used as
controls against nonspecific reactions. The blot was
developed using a secondary antibody which was horse radish
peroxidase labelled goat anti rabbit immunoglobulin antisera
used at a dilution of 1:1000 in antibody buffer.
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Figure 9: Second dot blot experiment. The vertical sample
columns are labelled with the test samples applied to the
membrane. Three dilutions of nurse shark serum were applied
in duplicate, as well as two dilutions of human serum and
two dilutions of lysozyme. Primary antibody used in all
samples are listed horizontally and include: rabbit
antihuman C3, goat antihuman C3, rabbit antihuman C4, goat
antihuman C4, goat antihuman C5, goat antihuman alpha 2
macroglobulin, normal rabbit serum, and rabbit anti-human
factor B antisera. Primary antisera against human
complement components, used in this blot, were raised in
either rabbits (indicated by R) or goats (indicated by G).
Primary antisera was applied to the blot at two different
dilutions, 1:30 and 1:15. Goat anti-rabbit immunoglobulin
antisera was raised in rabbits (labelled R). Rabbit anti-
goat immunoglobulin antisera was applied as a secondary
antibody when the primary antibody was of goat origin
(labelled G). Both secondary antibody preparations were
peroxidase labelled and applied at a dilution of 1:1000 in
antibody buffer.
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Figure 10: Third dot blot experiment. The vertical sample
columns are labelled with the sample applied to the
membrane. Three dilutions of nurse shark serum (1:10-
1:500), two dilutions of human serum and two dilutions of
two different samples (A and B) of lysozyme were blotted
onto the membrane. Primary antibodies used are listed
horizontally and include: rabbit anti-human C3, goat anti-
human C3, rabbit anti-human C4, goat anti-human C4, goat
anti-human 05, goat anti-human alpha 2 macroglobulin, normal
rabbit serum and rabbit anti-human factor B antisera. Goat
anti-rabbit immunoglobulin antisera was used as the
secondary antibody when primary antisera was raised in
rabbits (indicated by R) and rabbit anti-goat immunoglobulin
antisera when primary antibody was raised in goats
(indicated by G). Both secondary antibody preparations were
peroxidase labelled and applied at a dilution of 1:3000 in
antibody buffer.
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Figure 11: Fourth dot blot experiment using, the BioRad dot
blotting manifold (Biodot). Vertical columns are labelled
with the test samples that were applied to the membrane.
Horizontal rows are labelled with the primary antibodies
used to probe the samples and include: rabbit anti-human C3,
rabbit anti-human C4, rabbit anti-human factor B, rabbit
anti-human factor H antisera, non-immune rabbit serum (NRS),
rabbit gamma globulin fraction, and rabbit anti-goat
immunoglobulin antisera. All primary antibodies were used at
a dilution of 1:15 in antibody buffer. To test for
nonspecific binding of the secondary antibody to the blot,
it was added to all the samples to which no primary antibody
had been added. Secondary antibody was peroxidase labelled
rabbit anti-goat immunoglobulin antisera at a dilution of
1:1000 in antibody buffer.
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Figure 12: Western blot using the BioRad multiscreen
manifold. Membrane A contains proteins transferred from
preparative SDS-polyacrylamide gel in which human serum was
electrophoresed. Membrane B contains proteins transferred
from preparative SDS-polyacrylamide gel in which shark serum
was electrophoresed. Lanes for individual antisera were
formed on the membranes by placing them in the multiscreen
manifold. A list of primary antisera and the dilution at
which they were applied and the lanes containing them
appears below the blots. Goat anti-rabbit immunoglobulin
antisera was used as the secondary antibody where primary
antibody was of rabbit origin, and rabbit anti-goat
immunoglobulin antisera was used as the secondary antibody
in those lanes probed with primary antibody of goat origin.
Both secondary antibody preparations were peroxidase
labelled and used at a dilution of 1:1000 in antibody
buffer. Lane 19-20 contained prestained low molecular
weight protein standards which included: Phosphorylase B
(indicated by <) 106,000 daltons; Bovine serum albumin,
80,000 daltons; Ovalbumin, 49,500 daltons; Carbonic
anhydrase, 32,500 daltons; Soybean trypsin inhibitor, 27,500
daltons; and Lysozyme 18,500 daltons.
116
FIGURE 12
<K >> > ~ <K> <'K>> K~ K
K K K >K> <'~K~> K >~ '<' KKKK  <'K <' K
>K<K~~KKK\'K 'K> 'K " 'K
>K > <K <K'> > K> K K <'K
K 'K K K K ><'> K
K <'> K K <'<K> K K
K K K
K K 'K><' 'KK 'K> K
K K K K K K 'K K <' K K > <'<'K <K >K'KK> <K K
KKK>
K K< <KKKK ~ «K
K K <'<K>
K 'K>'K< K K <' <' K K> <K K> 'KK'KKK K>> K>
K K> K<' 'KK K<'K 'K >< K <K > >~
K K K~< 'K~<K~KK%~''KKK
K'KKK<' K ><'~ ~KKK >KK'< K K<'KK<
<'K> ~K > K> K K K<K K <'K < KK> > <K
K> <K 'K<'KKkK K "<'K KjK«~<KK K 'K 'KKK >< K< K'K~K><KKK<K
KKK<KK V «i> <K >KKK'KK <
'K> «< K > kK <K> 'K 'K > K K>> K K><K KKKKK>V'KK>K' '~> 'K' ' K
<'<KK'KKKK>KK' <>~K<K~K> KKK<>KK
K ~ 'K> K K
KY 'K K '«KK<>'>K'< ><
'K> <'K
>K~KK<K '""K K"'''' K K ~ <' KKK~
117
Figure 13: Coomassie Blue stained SDS Polyacrylamide gel.
The gel is a duplicate run simultaneous to the gel from
which the proteins were eluted and transferred to
nitrocellulose for immunoblotting (figure 14). Lane 4
contains human serum diluted 1:5; lane 3 contains nurse
shark serum diluted 1:5; lane 2 contains nurse shark serum
diluted 1:2; lane 1 contains prestained molecular weight
standards described in figure 12.
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Figure 14: Western blot developed with anti-human factor B
antisera. Lane 1 contains human serum diluted 1:5; lane 2
and 3 contain nurse shark serum diluted 1:5 and 1:2
respectively; lane 4 contains prestained molecular weight
standards described in figure 12. Primary antibody used to
probe this membrane was rabbit anti-human factor B antisera
at a dilution of 1:15. Secondary antibody was goat anti-
rabbit immunoglobulin antisera at a dilution of 1:1000.
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CONCLUSIONS
The objective of this study was to comprehensively
examine nurse shark serum for evidence of an alternative
pathway of complement activation. The presence and
functional characteristics of the classical pathway, in this
species, was firmly established by Jensen (1981) whose
studies did not indicate the presence of an alternative
pathway. Whether or not the alternative pathway is present
in Ginglymostoma cirratum, the nurse shark, has not been
determined to date although some investigators concluded,
based on the work of Jensen, that the alternative pathway
does not operate in the nurse shark (Koppenheffer, 1987;
Dodd, in press).
Ross and Jensen (1973) demonstrated the presence of a
molecule in nurse shark serum that is analogous to mammalian
C1, namely Cln. They have shown this molecule to be similar
in function to mammalian C1 in that it is the first
component to react in the classical complement cascade of
the nurse shark which consists of six functionally isolated
components (Cln, C2n, C3n, C4n, C8n, and C9n). Therefore,
Cln and C1 both have recognition and activation functions in
the classical pathways of shark and mammals respectively.
Similarily, Cln and mammalian Cl are both complexes of
subcomponents whose integrity is dependent on the presence
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of divalent metal ions. In the presence of EDTA, a chelator
of metal ions, Cn is completely inactivated. Once
inactivated by EDTA the activity of this molecule cannot be
restored by the addition of excess metal ions, unlike
mammalian C1 which readily reforms under these conditions.
Ross and Jensen were not able to conclusively prove that the
metal cation necessary to maintain the integrity of the Cln
molecule is calcium, as the molecule, once dissociated by
EDTA into its subcomponents, could not be induced to reform
by the addition of calcium ions under conditions
demonstrated to successfully restore activity of mammalian
C1 (Ross and Jensen, 1973). Experiments, in which magnesium
as well as other divalent cations that are chelated by EDTA
were added to dissociated-C1n did not result in
reassociation of the molecule. Thus, it cannot be said that
the reason EDTA-dissociated-C1n does not reform in the
presence of excess calcium ions is because another metal ion
is necessary for its integrity. It is more likely that the
removal of calcium ions from the Cln complex results in an
irreversible conformational change in one or more of its
subcomponents. The requirement for calcium ions in
classical complement pathway activity has been established
for mammals (Sim, 1981) as well as for representatives of
several other vertebrate classes (Ohta et al., 1984;
Sekizawa et al.,1984; Nonaka, 1981). Therefore an absolute
requirement for calcium is generally accepted as a criterion
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for defining classical complement pathway activity in the
serum of vertebrate species.
As EDTA also chelates magnesium ions, it predictably
shuts down alternative pathway activity as well as classical
complement activity as magnesium ions are required for
alternative pathway activity. In the mammalian alternative
pathway, magnesium ions are necessary for the binding of
factor B to C3b (Reid,1986). As EGTA was originally used to
titrate calcium ions in the presence of magnesium ions,
(Schmid and Reilly, 1957) this chelator can be used to
selectively chelate calcium ions from a solution while
leaving magnesium ions available. Thus, serum chelated with
EGTA would be expected to be devoid of available calcium
ions while still maintaining free magnesium ions. Hemolytic
activity seen in assays of EGTA treated serum can then be
attributed to a calcium independent activation pathway. The
alternative pathway in mammals and lower vertebrate species
does not require calcium ions, indicating that a calcium-
dependent recognition/activation molecule (i.e. Cl) is not
required to initiate this pathway. Calcium-independent
activity (i.e. alternative pathway) has been demonstrated
in all classes of vertebrates with the exception of the
cartilaginous fish. This study has demonstrated, for the
first time, that calcium-independent lytic activity does
exist in nurse shark serum, as EGTA-chelated serum retained
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hemolytic activity against mammalian target erythrocytes at
concentrations of EGTA up to 50 mM. These results indicate
that a lytic system does exist in nurse shark serum that
most probably bypasses the classical complement pathway
recognition/activation molecule (Cln) to produce lysis of
target cells through an alternative mechanism of activation.
Chelating of nurse shark serum with EGTA results in a
statistically significant drop in hemolytic titre from that
of unchelated serum using rabbit, horse, sheep (sensitized
and unsensitized) and bovine (sensitized and unsensitized)
target erythrocytes. An initial significant drop in
hemolytic titre from control levels occurs when serum is
chelated with 5 mM EGTA, followed by smaller decreases in
titre with increasing concentration of EGTA. These
observations suggest that 5 mM EGTA is sufficient to remove
available calcium ions from nurse shark serum. According to
a Sea World study (Murru, 1984) a calcium level of 3mM is
representative of the species. A concentration of 5 mM EGTA
should be sufficient to remove all the calcium ions as EGTA
combines with calcium in a 1:1 ratio (Schmid and Reilly,
1957). The minimal decreases in hemolytic titre when EGTA
concentration is increased may be due to a weak association
of EGTA with magnesium limiting the activity. EGTA has an
association constant (Ka) of 1 X 105 for magnesium versus 1
X 1011 for calcium and therefore it preferentially, but not
exclusively, binds calcium. EDTA forms stable complexes
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with both calcium and magnesium, with Ka values of 1 X 10'
and 1 X 109 respectively (Fine et al. 1972). EDTA
completely inhibits the lytic activity of nurse shark serum
because it removes all available calcium and magnesium. In
those instances where a low level of lytic activity remained
in shark serum chelated with 10 mM EDTA the serum samples
also demonstrated a proportionately higher level of activity
against the corresponding target cell when chelated with
EGTA. This most likely reflects the higher initial levels
of magnesium present in these sera. It could possibly be
argued that the serum calcium level (3 mM) obtained by Murru
(1984) was not representative of normal levels in nurse
shark serum so that even 25 mM EGTA is insufficient to
remove all available calcium ions from the serum, i.e. the
residual hemolytic activity would then be due to the
classical pathway. If this were the case, the results would
not show such an initial large drop in hemolytic titre when
serum is chelated with 5 mM EGTA followed by small decreases
as EGTA levels increase. Activated C1 initiates an
amplification phase of the classical pathway whereby many
molecules of C4 are cleaved. If sufficient calcium remains
to activate C1n in chelated shark serum, the residual
hemolytic activity would be expected to be at levels closer
to control levels. One can conclude from these data that
removal of calcium ions from nurse shark serum by EGTA is
responsible for the significant decrease in hemolytic
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activity noted, and that a calcium-independent lytic system,
a characteristic criterion of alternative pathway activity,
is responsible for the lytic activity remaining in shark
serum. Furthermore, these results indicate calcium is
necessary for the integrity of Cln and thus the activity of
the classical pathway. If it were not, no loss of lytic
activity would occur on chelating nurse shark serum with
EGTA.
As lytic activity remained in serum chelated with EGTA
but not in serum chelated with an equivalent concentration
of EDTA, a cation that is bound by EDTA but not EGTA has to
be required by the calcium-independent pathway described
above. Alternative pathway activity in other species is
dependent on magnesium ions. Therefore, the effect of added
magnesium ions on the hemolytic activity of EGTA chelated
shark serum was evaluated. The addition of magnesium ions
to shark serum, chelated with 20 mM EGTA, increased
hemolytic titres significantly over titres of serum chelated
with 20 mM EGTA to which no magnesium had been added. This
increase in activity was seen with all mammalian erythrocyte
targets tested. These observations establish that the
calcium-independent lytic system, is enhanced by added
magnesium ions. This is in accordance with accepted
criteria of alternative pathway activity namely, the ability
to lyse target erythrocytes in the presence of magnesium
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ions alone, i.e. in the absence of calcium ions.
The efficacy of EGTA as a chelator of calcium ions is
dependent on pH (cation binding does not occur at pH values
below 6.4) (Platts-Mills and Ishizaka, 1974). The addition
of magnesium ions to buffers containing EGTA results in a
drop in pH, thus if the pH is not adjusted when magnesium is
added to EGTA-containing assay buffers bound calcium would
be released by the chelator. For this study, the pH of
magnesium-containing EGTA buffers was adjusted upwards with
1 N NaOH to 7.4 to eliminate such a loss of effectiveness of
the chelator. Should however, a drop in pH occur
inadvertantly, classical pathway activity cannot be restored
by the availability of released calcium or magnesium ions as
a loss of Cln activity by removal of metal cations is
irreversible. Therefore the increase in hemolytic activity
observed in chelated sera on the addition of magnesium ions
cannot be due to the availablity of calcium ions released by
the chelator. From experimental results, it is clear that a
calcium-independent, magnesium-dependent hemolytic pathway
operates in nurse shark serum. As these are characteristics
typical of the mammalian alternative complement pathway, it
would be reasonable to state that the alternative pathway of
complement activation has been unequivocally demonstrated
in this primitive animal.
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This study has shown that some differences in the
activity of the alternative pathway of mammals and sharks do
exist. Whereas the lysis of rabbit and horse erythrocytes
in the presence of EGTA occurs via the alternative pathway
in other vertebrate species (Platts-Mills and Ishizaka,
1974; Ohta etal.,1984), the lysis of sheep erythrocytes, by
human, bird and rainbow trout (Nonaka,1984) complement, is
completely blocked by EGTA, indicating lysis to be
exclusively via the classical pathway. In the nurse shark
however, significant lysis of these target cells occured
under conditions which allowed only alternative pathway
activity. If the lysis of sheep cells by nurse shark
complement is due to the alternative pathway then shark
serum, chelated with EDTA should regain activity on the
addition of magnesium ions. Experiments showed that the
lytic activity of nurse shark serum, chelated with 10 mM
EDTA, against unsensitized sheep and sensitized sheep and
bovine erythrocytes can in fact be restored by the addition
of magnesium ions. As Cln of the nurse shark classical
pathway has been shown to be irreversibly inactivated by
EDTA, this restoration of activity by the addition of
magnesium ions has to be due to the activity of a lytic
pathway that does not require Cln as the initial
recognition/activation molecule.
It has been proposed (Pangburn and Muller-Eberhard,
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1980) that activators of the alternative pathway provide a
site in which factor B and C3b are protected from
degradation by the endogenous control proteins factor H and
C3b inactivator(factor I). The complement control proteins
of nurse sharks may be different from those of mammals,
raising the possibility of a site on the surface of sheep
erythrocytes which protects C3/C5 convertase proteins from
inactivation by shark control proteins. Kaidoh and Gigli
(1987) have demonstrated that the serum of lower vertebrates
contain factors that are able to generate cleavage fragments
of C3b and C4b identical to those produced by mammalian
control proteins C4bp and C3b inactivator (factor I) and
factor H respectively suggesting the presence of analogous
control proteins in these species. However, in this study,
the serum of cartilaginous fish was not able to produce
these fragments from human C3 and C4. A possible
explanation for the failure of shark serum to produce the
fragments could be that shark control proteins are different
and do not recognize human C3 or C4, or alternatively shark
proteins analogous to human C3 and /or C4 are structurally
and perhaps functionally different and therefore subject to
different control proteins or mechanisms. Either situation
may exist in the nurse shark. These possible differences
might also explain why the lysis of sheep erythrocytes by
nurse shark serum occurs via the alternative pathway. It
has also been shown (Kaidoh and Gigli, 1987) that the
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control proteins of teleost are calcium dependent. It might
be that shark complement control proteins are also calcium
dependent, therefore, in the presence of EGTA these proteins
are inactivated which allows sheep cells to be lysed by the
alternative pathway. Similar to shark serum activity, lysis
of sheep erythrocytes by cobra (Vogel and Muller-
Eberhard,1984) and carp (Matsuyame,1987) serum has been
shown to occur under conditions of alternative pathway
activity.
Activation of nurse shark complement by known
activators of the mammalian alternative pathway was
attempted in this investigation. Initial experiments
demonstrated that zymosan was able to deplete nurse shark
serum of hemolytic activity in the presence of EGTA (which
allows only alternative pathway activity) and in the absence
of EGTA (both pathways operate). Nurse shark complement was
found to be activated by zymosan and complete depletion of
hemolytic activity occurred in serum chelated with 20 mM
EGTA. However, when unchelated serum was incubated with
zymosan and then assayed against sensitized sheep
erythrocytes in DGVB++ a loss of hemolytic activity was
observed but hemolytic activity was not totally depleted
indicating that sufficient terminal components remained to
affect limited lysis of the target cells via the classical
pathway. It is also possible that, in the absence of the
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chelator, some activation of the classical pathway occurred
when serum was incubated with zymosan without chelator as it
is very likely nurse shark serum contains natural antibodies
to zymosan as does human serum (Nelson, 1959). The
conclusions which can be drawn from this study are that
zymosan can activate nurse shark alternative pathway and to
a limited extent, through the interaction with shark natural
antibody, the classical pathway as well. However,
activation of the classical pathway could not have depleted
the terminal components or early acting components of the
classical pathway. In subsequent experiments using serum
samples from additional individuals, reduction of hemolytic
activity of unchelated nurse shark serum by incubation with
zymosan was confirmed. Hemolytic activity of chelated serum
from one of these individuals was also depleted completely
by zymosan confirming activation of the alternative pathway.
Chelated serum from the other individual showed no
consistent reduction in hemolytic activity as a result of
incubation with zymosan indicating no activation of the
alternative pathway occurred. It is possible, since this
individual was the largest animal used in this study, a
difficult capture may have resulted in activation of
complement in vivo through the release of acute phase
proteins. The hemolytic titre of unchelated serum from both
individuals was reduced by incubation with zymosan. These
results indicate zymosan activates nurse shark complement
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directly via the alternative pathway and through
sensitization with natural antibody to zymosan via the
classical pathway. It would appear from these results that
if only the alternative pathway is activated all of the
terminal components are not used up as would be expected.
Rather an early acting component of the alternative pathway
is the limiting factor.
LPS, an activator of the mammalian alternative
pathway, reduced the hemolytic activity of shark serum,
however, the decrease in activity was observed only when
unchelated nurse shark serum was activated. This suggests
that the classical pathway only is activated by LPS. The
lipid moeity of LPS is known to activate the classical
pathway of mammals directly while the polysaccharide portion
activates the alternative (Klein,1990). Therefore, it is
possible that the polysaccharide fails to activate shark
complement whereas lipid A of LPS is an activator of the
classical pathway.
Under our experimental conditions inulin and cobra
venom factor failed to activate shark complement as a
reduction of hemolytic activity of nurse shark serum was not
observed after incubation with either inulin or cobra venom
factor. In the case of inulin, it is possible that it does
not activate nurse shark complement at concentrations
133
similar to those used for zymosan and LPS and activation may
be achieved at higher concentrations. The concentration of
CVF employed may also have been too low and thus the
possiblity of it being an activator of nurse shark
complement cannot be ruled out. It is also possible that
the shark complement counterpart of factor B is not
functionally compatible with CVF which in the mammalian
system functions as a C3b substitute. Shark complement
control proteins, as yet unidentified, could be efficient at
degrading the "CVFBb" complex unlike the control proteins of
mammals. Failure to produce a loss of hemolytic activity
does not necessarily indicate the failure of a substance to
activate nurse shark complement. Complement components may
be activated without activation of the membrane attack
complex. As the lysis of foreign erythrocytes is not the
primary function of complement in vivo, it is possible that
the alternative pathway may be activated without lysis
occuring. Opsonization is considered to be a primitive
function of complement (Farries et al.,1990); it may be that
nurse shark serum, when activated, does not lyse targets but
rather brings about the opsonization of target particles.
Such activity has been demonstrated in mammalian serum when
activated by cobra venom factor from the Thailand cobra
(Naia haje), which interacts with factor B but does not
produce a functional C5 convertase thus leaving the proteins
of the membrane attack complex intact.
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Although results obtained from dot and Western blots
did not yield conclusive evidence for the presence, in nurse
shark serum, of proteins that antigenically cross react with
antisera raised to mammalian complement proteins, the
possibility that antigenic relationships exist cannot be
ruled out. Further refinement of these procedures may yet
produce specific reactions between proteins in nurse shark
serum and antibodies raised to human complement components.
For example, an increase in incubation time of the primary
antibody with shark serum proteins on the membrane in
Western blots may facilitate the binding of the antibody
even if the "fit" is not exactly perfect. Another
modification to the procedure which might yield positive
reactions in Western blots is to increase the concentration
of primary antibody or employ primary antisera raised to
complement components of lower vertebrate species.
Activated nurse shark serum may give a positive reaction
where unactivated serum failed to do so as "activation" may
expose hidden epitopes or the configuration of epitopes may
be changed. This has been demonstrated using activated
cobra serum probed with antiserum to human C3 (Koppenheffer,
1987).
Nonspecific reaction may be decreased in dot blots by
incubation of the primary and secondary antibodies with
nurse shark serum on the membrane at 370C rather than at
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room temperature. IgG, the primary antibody class in hyper
immune mammalian antiserum reacts better at 370C than at
room temperature whereas IgM, the primary antibody class of
nurse shark natural antibody (Rudikoff et al., 1970) reacts
best at 4-200. Natural antiboby is very likely to be the
factor responsible for the nonspecific reactions seen in dot
blots. These nonspecific reactions may also be reduced by
the use of an alternate blocking agent such as BLOTTO.
This study has proven conclusively, for the first
time, that the alternative pathway of complement activation
is present in a representative of the cartilagenous fish.
The requirements for divalent cations by the two complement
pathways of this species are analogous to those found in
higher vertebrates. These studies suggest that biological
substances that activate the nurse shark alternative pathway
and classical pathway are not as restricted as that of
higher vertebrates. As the range of substances that
activate the mammalian alternative pathway is extremely
diverse, no common factor has been found that defines a
substance as an activator or a nonactivator. One factor,
sialic acid, has been shown to restrict activation of the
mammalian alternative pathway (Kazatchine et al., 1979).
Sialic acid is found on the surface of sheep erythrocytes
and its removal has been shown to permit activation of the
mammalian alternative pathway by sheep erythrocytes. As
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sheep erythrocytes can activate the alternative pathway in
the nurse shark, it is possible that sialic acid does not
restrict activation of this pathway in nurse shark serum.
Alternatively, sialic acid on the surface of sheep
erythrocytes is masked by shark natural antibody. It is
also possible, given the level of IgM class natural antibody
to sheep erythrocytes in shark serum, that immune complexes
or IgM aggregates may form during hemolytic assays providing
activation of nurse shark alternative pathway and subsequent
lysis of the target cells.
Given that it can now be said that both complement
activation pathways exist in the primitive nurse shark, the
divergence of these two pathways must have occured prior to
the evolutionary divergence of the sharks from the higher
vertebrates over 300 million years ago. This fact implies
that both pathways are phylogenetically ancient defense
mechanisms and perhaps have evolved not one from the other
but parallel to one another with some "borrowing" of
proteins between pathways over evolutionary time. More
conclusive proof of this possibility awaits definition of
alternative pathway proteins of the shark as well as those
of Agnathans and invertebrates.
137
REFERENCES
Abbas, A.K., Lichtman, A.H. and Pober, J.S. 1991. In
Cellular and Molecular Immunology. W.B. Saunders Co.,
Philadelphia, PA. 259-282.
Alexander, R.G. and Steiner, L.A. 1980. The first component
of complement from the Bullfrog, Rana catesbeina: functional
properties of C1 and isolation of subcomponent C1g. J.
Immunol. 124, 1418.
Bentley, D. R. and Campbell, R.D. 1986. C2 and factor B:
Structure and genetics. Biochem. Soc. Symp. 51 7.
Brade, E.J., Cook, C.T., Shin, H.S. and Mayer, N.M. 1972.
Studies on the properdin system: Isolation of a heat-labile
factor from guinea pig serum related to a human glycine-rich
beta glycoprotein (GBG or factor B). J. Immunol. 109, 1174.
Bryant, R.E. and Jenkins, D.E. 1968. Calcium requirements
for complement dependent hemolytic reactions. J. Immunol.
101, 664.
Canicatti, C. and Tschopp, J. 1989. Relationship between
vertebrate channel forming proteins and invertebrate
haemolysin. Dev. Comp. Immunol. 13, 377.
138
Campbell, D.H., Garvey, J.S., Cremer, N.E. and Sussdorf,
D.H. 1970. In Methods in Immunology. WA Benjamin Inc. New
York, NY. 120.
Cowan, K.M. 1958. Phage neutralization to determine
properdin levels. Science 128, 778.
Day, N.K.B., Gerwurtz, H., Johannsen, R., Finstad, J., and
Good, R.A. 1970. Complement and complement-like activity in
lower vertebrates and invertebrates. J. Exp. Med. 132, 941.
Dodds, A.W. and Day, A.J. The phylogeny and evolution of the
complement system. In press.
Doolittle, R.F. 1985. The genealogy of some recently evolved
vertebrate proteins. Trends Biochem. Sci. 10, 233.
Ellis, M.G., Lamont, S.J. and Arp, L.H. 1989.
Characterization of complement activity in turkeys: evidence
for classical and alternative complement pathways. Poultry
Science. 68, 646
Farries, T.C., Steuer, K.L. K. and Atkinson, J.P. 1990.
Evolutionary implication of a new bypass activation pathway
of the complement system. Immunol. Today. 11 78.
139
Fearon, D.T. and Austen, K.F. 1977. Activation of the
alternative complement pathway with rabbit erythrocytes by
circumvention of the regulatory action of endogenous control
proteins. J. Exp. Ned. 146, 22.
Fine, D.P., Marney, S.R., Colley, D.G., Sergent, J.S. and
Des Prez, R.M. 1972. C3 shunt activation in human serum
chelated with EGTA. J. Immunol. 109, 807.
Gotze, 0. and Muller-Eberhard, H.J. 1971. The C3 activator
system: an alterantive pathway of complement activation. J.
Exp. Med. 134, 90s.
Gotze, 0. and Muller-Eberhard, H.J. 1976. The alternative
pathway of complement activation. Adv. in Immunol. 24, 1.
Hyder-Smith, S. and Jensen, J.A. 1986. The second component
(C2n) of the nurse shark complement system: Purification,
physicochemical characterization and functional comparison
with guinea pig C4. Dev. Comp. Immunol. 10. 191.
Jensen, J.A., Sigel, M.M., and Ross, G.D. 1968. Natural
antibody (An) and compement (C') of the nurse shark. Fed.
Proc. 27, 491.
Jensen, J.A. 1969. A specific inactivator of mammalian C4
140
isolated from nurse shark (Gin mostoma ciratu serum. J.
Exp. Med. 130, 217.
Jensen, J.A., Fuller, L., and Iglesias, E. 1973. The
terminal components of the nurse shark (Gincl mostoma
cirratum) complement system. J. Immunol. 111, 306.
Jensen, J.A., Festa, E., Smith, D.S., and Cayer, M. 1981.
The complement system of the nurse shark: hemolytic anbd
comparative characteristics. Science 214, 566.
Jurd, R.D. 1983. Specialization of the teleost and anuran
immune response: A comparative critique. In Fish Immunology.
Academic Press. 9.
Kabat, E.A. and Mayer, M. N. 1961. In Experimental
Immunochemistry. Charles C Thomas Springfield, IL. 133.
Kawaguchi, S., Muramatsu, S. and Mitsuhashi, S. 1978.
Natural haemolytic activity of snake serum. I. Natural
antibody and complement. Dev. Comp. Immunol. 2, 287.
Kazatchine, N.D., Fearon, D.T. and Austen, K.F. 1979. Human
alternative complement pathway: Membrane associated sialic
acid regulates the competition between factor B and beta 1 H
for cell bound C3b. J. Immunol. 122, 75.
141
Klein, J. 1990. In Immunology. Blackwell Scientific
Publications Boston, MA.
Koppenheffer, T.L. 1986. Activation of alternative
complement pathway by both high and low molecular weight
turtle antibodies. Am. Zool. 26, 86A.
Koppenheffer, T.L. 1987. Serum complement systems of
ectothermic vertebrates. Dev. Comp. Immunol. 11, 279.
Laemmli, U.K. 1970. Cleavage of structural proteins during
the assembly of the head of bacteriophage T4. Nature. 227,
680.
Marney, S.R. and Des Prez, R.M. 1969. Comparison of the
effects of divalent ion chelating agents on complement-
mediated hemolysis on rabbit and human serum. J. Immunol.
103, 1044.
Matsuyama, H., Tanaka, K., Nakao, M., and Yano, T. 1988.
Characterization of the alternative complement pathway of
carp. Dev. Comp. Immunol. 12, 403.
Medicus, R.G., Gotze, 0., and Muller-Eberhard, H.J. 1976a.
Alternative pathway of complement: Recruitment of precursor
properdin by the labile C3/C5 convertase and potentiation of
142
the pathway. J. Exp. Med. 144, 1076.
Medicus, R.G., Schreiber, R.D., Gotze, 0. and Muller-
Eberhard, H.J. 1976b. A molecular concept of the properdin
pathway. Proc. Natl. Acad. Sci. 73, 612.
Muller-Eberhard, H.J. 1969. Complement. Ann. Rev. Biochem.
38, 389.
Muller-Eberhard, H.J. and Schreiber, R.D. 1980. Molecular
biology and chemistry of the alternative pathway of
complement. Adv. in Immunol. 29,1.
Murru, F.L. 1984. Preliminary baseline blood parameters for
several sharks. Am. Assoc. Zoo. Parks and Aquariums, Ann.
Conf. Proceedings. 333.
Nelson, R.A. 1958. An alternative mechanism for the
properdin system. J. Exp. Med. 108, 515.
Nelson, B. and Ruddy, S. 1979. Enhancing role of IgG in
lysis of rabbit erythrocytes by the alternative pathway of
human complement. J. Immunol. 122, 1994.
Nonaka, M., Yamaguchi, N., Natsuume-Sakai, S. and Takahashi,
M. 1981. The complement system of the rainbow trout (Salmo
143
gairdneri) I. Identification of the serum lytic system
homologous to mammalian complement. J. Immunol. 126, 1489.
Nonaka,N. Fujii, T. Kaidoh, T. and Natsuume-Sakai, S. 1984.
Purification of lamprey complement protein homologous to the
third component of the mammalian complement system. J.
Immunol. 133, 3242.
Ohta, M., Okada, N., Yamashina, I. and Kawasaki, T. 1990.
The mechanism of carbohydrate mediated complement activation
by the serum mannan binding protein. J. Biol. Chem. 256,
1980.
Ohta, H. Yoshikawa, Y., Kai, C. Yamanouchi, K. and Okada, H.
1984. Lysis of horse red blood cells mediated by antibody-
independent activation of the alternative pathway of chicken
complement. Immunology. 52, 437.
Pangburn, M.K. and Muller-Eberhard, H.J. 1980. Relation of a
putative thiolester bond in C3 to activation of the
alternative pathway and the binding of C3b to biological
targets of complement. J. Exp. Med. 152, 1102.
Pettey, C.L. and McKinney, E. C. 1983. Temperature and
cellular regulation of spontaneous cytotoxicity in the
shark. Eur. J. Immunol. 13, 133.
144
Pillemer, L. Blum, L., Lepow, I.H., Ross, O.A., Todd, E.W.
and Wardlaw, A.C. 1954. The properdin system and immunity:
I. Demonstration and isolation of a new serum protein,
properdin, and its role in immune phenomena. Science. 120,
279.
Pillemer, L., Schoenberg, M.D., Blum, L. and Wurz, L. 1955.
Properdin system and immunity: II. Interaction of the
properdin system with polysaccharides. Science. 122, 545.
Platts-Mills, T.A.E. and Ishizaka, K. 1974. Activation of
the alternative pathway of human complement by rabbit cells.
J. Immunol. 113, 348.
Polhill, R.B., Newman, S.L., Pruitt, K.M. and Johnson, R.B.
1978. Kinetic assessment of alternative complement pathway
activity in a hemolytic system. J. Immunol. 121, 371.
Quigley, J.P. and Armstrong, P.B. 1985. A homologue of alpha
2 macroglobulin purified from the haemolymph of the
horseshoe crab Limulus polyphemus. J. Biol. Chem. 260,
12715.
Reid, K.B.M. 1981. The proteolytic activation systems of
complement. Annu. Rev. Biochem. 50, 433.
145
Reid, K.B.M. 1986. Activiation and control of the complement
system. Essays in Biochem. 22, 27.
Robey, F.A. and Liu, T.Y. 1981. Limulin: a C-reactive
protein from Limulus polyphemus. J. Biol. Chem. 256, 969.
Roitt, I., Brostoff, J. and Male, D. 1985. In Immunology. C
V Mosby Co. St. Louis, NO.
Ross, G.D. and Jensen, J.A. 1973. The first component (Cn)
of the complement system of the nurse shark (Ginglymostoma
cirratum). I. Haemolytic characteristics of partially
purified Cln. J. Immunol. 110, 175.
Ross, G.D. and Jensen, J.A. 1973. The first component (Cln)
of the complement system of the nurse shark (Ginglymostoma
cirratum). II. Purification of the first component by
ultracentrifugation and studies of its physicochemical
properties. J. Immunol. 110, 911.
Rudikoff, S., Voss, E.W. and Sigel, M.M. 1970. Biological
and chemical properties of natural antibodies in the nurse
shark. J. Immunol. 105, 1344.
Sandberg, A.L., Osler, A.G., Shin, H.S. and Oliveira, B.
1970. The biologic activityes of guinea pig antibodies. II.
146
Modes of complement interaction with inmunoglobulins. J.
Immunol. 104, 329.
Sandberg, A.L., Oliveira, B. and Osler, A.G. 1971. Two
complement interaction sites in guinea pig immunoglobulins.
J. Immunol. 106, 282.
Sandberg, A.L. and Osler, A.G. 1971. Dual pathways of
complement interaction with guinea pig immunoglobulins. J.
Immunol. 107, 1268.
Schenken, H.A. and Ruddy, S. 1981. The role of
immunoglobulins in alternative complement pathway activation
by zymosan. I. Human IgG with specificity for zymosan
enhances alternative pathway activation by zymosan. J.
Immunol. 126, 7.
Schmid, R.W. and Reilly, C.n. 1957. A new complexon for
titration of calcium in the presence of magnesium. Anal.
Chem. 29, 264.
Sekizawa, A., Fujii, T. and Katagiri, C. 1984. Isolation and
characterization of the third component of complement of the
serum of the clawed frog Xenopus laevis. J. Immunol. 133,
1436.
147
Simmons, A. 1980. In Technical Hematology. Third ed. J.B.
Lippincott Co. Philadelphia PA.
Sottrup-Jensen, L., Stepnik, T.N., Kristensen, T., Lonblad,
P.B., Jones, C.M., Wierzbick, D.M. Magnusson, S., Domdey,
H., Wetsel, R.A., Lundwall, A., Tack, B.F. and Fey, G.H.
1985. Common evolutionary origin of alpha 2 macroglobulin
and complement components C3 and C4. Proc. Natl. Acad. Sci.
USA. 82, 9.
Spycher, S.E., Arya, S., Isenman, D.E. and Painter, R.H.
1987. A functional thioester containing alpha 2
macroglobulin homologoue isolated from the haemolymph of the
American lobster Homarus americanus. J. Biol. Chem. 262,
14606.
Springer, V.G. and Gold, J.P. 1989. In Sharks in Question.
Smithsonian Institution Press. Washington D.C.
Toussaint, A.J. and Muschel, L.H. 1959. Neutralization of
bacteriophage by normal serum. Nature. 183, 1825.
Towbin, H., Staelhelin, T. and Gordon, J. 1979.
Electrophoretic transfer of proteins from polyacrylamide
gels to nitrocellulose sheets: Procedure and some
applications. Proc. Natl. Acad. Sci. 76, 4350.
148
Vogel, C.W. and Muller-Eberhard, H.J. 1985. The cobra
complement system I. The alternative pathway of activation.
Dev. Comp. Immunol. 9, 311.
Volkanis, J.E. 1986. Structure and molecular genetics of
complement proteins. The year in Immunol. 2, 164.
149
Appendix 1
Collect Animal Sex of Size of Water
Date Number Animal Animal Temp.
09/25/91 092591-1 F 2'5" 31'C
09/25/91 092591-2 F 3' 310 C
09/25/91 092591-3 F 2'8" 310C
10/18/91 101891-1 ? 2'6" 26C
10/18/91 101891-2 N 2'6" 2600
TAG#186
10/18/91 101891-3 M 3'4" 260C
TAG#88
10/18/91 101891-5 2'6" 290C
10/18/91 101891-6 ? 2' 260C
11/14/91 111491 M 2'6" 210C
TAG# 186
01/09/92 TAG#88 M 31411 2400
01/09/92 TAG#186 N 2'6" 240C
01/09/92 TAG#238 F 2'2" 240 C
01/09/92 TAG#241 F 2' 240C
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Collect Animal Sex of Size of Water
Date Number Animal Animal Temp.
01/09/92 TAG#242 N 30 24 0C
01/09/92 TAG#463 M 4'4" 24®C
01/09/92 TAG#244 F 3' 240 C
01/09/92 TAG#248 N 4' 240C
02/27/92 TAG#453 N 27" 260C
02/27/92 TAG#466 N 31" 260C
02/27/92 TAG#230 N 53" 260C
02/27/92 TAG#241 F 30" 260 C
02/27/92 TAG#465 F 28" 260 C
02/27/92 TAG#455 N 28" 260 C
02/27/92 TAG#477 F 40" 260C
02/27/92 TAG#489 F 36" 26 0C
03/19/92 TAG#246 4' 25 0C
03/19/92 TAG#463 N 4'4" 250C
03/19/92 TAG#452 F 34" 25 0C
03/19/92 TAG#489 F 36" 250C
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Collect Animal Sex of Size of Water
Date Number Animal Animal Temp.
03/19/92 TAG#238 F 34" 25 0C
03/19/92 TAG#242 30" 25'C
04/30/92 TAG#456 6' 21 0C
04/30/92 TAG#248 M 3'5" 21 0C
04/30/92 TAG#489 F 3'5" 210 C
04/30/92 TAG#463 M 4 21 0C
04/30/92 TAG#457 F 3' 210 C
04/30/92 TAG#186 M 2'6" 21'C
04/30/92 TAG#238 F 3' 210 C
04/30/92 TAG#88 M 3'41 21 0C
04/30/92 TAG#242 N 2'6" 21 C
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Appendix 2
Sources of reagents and chemicals
Isotonic saline (0.15 M NaCl, ACS grade) Scientific Products
McGaw Park, IL
Dextrose, bacteriological grade Difco Laboratories
Detroit MI
Barbital (Barbitone; Sigma Chemical Co.
5,5-diethylbarbituric acid; Veronal) St. Louis, MO
sodium salt
Barbital (Barbitone;
5,5-diethylbarbituric acid; Veronal)
Magnesium chloride, hexahydrate
ACS grade
Calcium chloride, anhydrous
approx. 97%
Ethylendiaminetetra acetic acid
disodium salt dihydrate
Ethyleneglycol-bis- (beta-amino ethyl
ether) N,N,N,N-tetra acetic acid
approx. 97% anhydrous
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Zymosan A from Saccharomyces
cerevisiae
Lipopolysaccharide from Salmonella
typhosa
Inulin from dahlia tubers
Cobra venom factor, Naia naja
kaouthia
Sodium chloride, ACS grade Mallinckrodt
Paris, KY
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Appendix 3
Composition of TA- - an A- GV - assay buffers
mM Chelator ml of Stock M1 of 5 X ml of 2%
Gelatin
5 5 20 5
7. 7..5 20 5
10 10 2 5
12.5 12.5 20
15 15 20 5
17.5 17.5 20 5
20 20 20 5
22.5 22.5 0 5
25 2 20 5
30 30 20 5
35 35 2 5
40 0 20 5
45 45 20 5
50 50 20 5
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Appendix 4
Volume of nurse shark serum to chelator
ul of Nurse Shark ul of Stock Final
Serum Chelator Concentration of
Chelator
950 50 5
900 100 10
850 150 15
800 200 20
750 250 25
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Appendix 5
Composition of 20 mM EGTA-GVB buffers used in magnesium
reconstitution experiments
Final mlofX mlof 2% mi of ml of
Mg++ Veronal Gelatin Stock Stock
Level MgCl 2  EGTA
0mM 20 5 0 20
1mM 20 5 1 20
5 mM 20 5 5 20
10 mM 20 5 10 20
15 mM 20 5 15 20
20mM 20 5 20 20
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Appendix 6
Outline of protocol for activation of nurse shark serum by
known activators of the mammalian alternative pathway
Final ml of Shark ml of Stock ml of Buffer
Activator Serum Activator (DGVB++ or
Level EGTA-Mg-GVB
O mg/ml 1 0 1
1 mg/ml 1 0.1 0.9
5 mg/ml 1 0.5 0.5
10 mg/ml 1 1 0
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Appendix 7
Source and product description of primary and secondary
antisera preparations for immunoblotting
Janssen Biochemica, distributed in US by Accurate
1. Rabbit antihuman C3b
Protein conc. 24 mg/ml
Antibody titre 0.15 mg/ml
2. Rabbit antihuman C4
Protein conc. 45 mg/ml
Antibody titre 0.46 mg/ml
3. Rabbit antihuman C5
Protein conc. 28 mg/ml
Antibody titre 0.18 mg/ml
4. Rabbit antihuman factor B
Protein conc. 16 mg/ml
Antibody titre 0.52 mg/ml
5. Rabbit antihuman factor H
Protein conc. 23 mg/ml
Antibody titre 1.45 mg/ml
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Cedarlane, Hornby Ontario
1. Normal rabbit serum
Lampire biolocricals, Pipersville, PA
1. Rabbit Gamma globulin fraction
Protein conc. 20 mg/ml
2. Normal goat serum
Kallestad, Chaska MN
1. Goat anithuman alpha 2 macroglobulin
Specific antibody conc. 5.22 mg/ml
2. Goat antihuman C3
Total protein 126 mg/ml
Specific antibody conc. 9.57 mg/ml
3. Goat antihuman C4
Total protein 55.6 mg/ml
Specific antibody conc. 6.5 mg/ml
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Cappell, West Chester PA
1. Goat antihuman C5
Total protein 18 mg/ml
2. Goat antihuman C3
Total protein 67.5 mg/ml
Antibody protein 10 mg/ml
3. Rabbit antigoat IgG (whole molecule) peroxidase
conjugated
BioRad, Richmond,. CA
1. Goat antirabbit IgG (heavy and light chain specific)
horse radish peroxidase conjugated
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